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ABSTRACT
Learn biological meaningful representations with transfer learning
by
Di He
Advisor: Lei Xie, Ph.D
Machine learning has made significant contributions to bioinformatics and computational biol­
ogy. In particular, supervised learning approaches have been widely used in solving problems such
as bio­marker identification, drug response prediction, and so on. However, because of the limited
availability of comprehensively labeled and clean data, constructing predictive models in super­
vised settings is not always desirable or possible, especially when using data­hunger, red­hot learning
paradigms such as deep learning methods. Hence, there are urgent needs to develop new approaches
that could leverage more readily available unlabeled data in driving successful machine learning ap­
plications in this area.
In my dissertation, I focused on exploring and designing deep learning­based unsupervised
representation learning methods. A consistent scheme of these methods is that they construct a low­
dimensional space from the unlabeled raw datasets, and then leverage the learned low­dimensional
embedding explicitly or implicitly for diverse downstream supervised tasks. Although progresses
have been made in recent years, most deep learning applications in biomedical studies are still in
their infancy. It remains a challenging task to fully extract the biological meaningful information
from a biomedical dataset such as multi­omics data to support predictive modeling for practical tasks
of interest. To improve the biological relevance of learned representations, innovative approaches
that could better integrate mulit­omics data and utilize their specific characteristics and natural ”anno­
tations” are needed.
Abstract v
Hence, we proposed two approaches, namely, Cross LEvel Information Transmission (CLEIT)
network and Coherent Cell­line Tissue Deconfounding Autoencoder (CODE­AE). Specifically,
CLEIT aims to leverage the hierarchical relationships among omics data at different levels to drive
the biologically meaningful representation learning, and CODE­AE learns biologically meaningful
representations by explicitly de­confounding the con­founding factors such as data source origins.
As the benchmark results showed, these two methods are able to improve knowledge transfer be­
tween multi­omics data, and in­vitro and in­vivo samples respectively, and significantly boost re­
spective performance in drug response prediction task. Thus, they are potentially powerful tools for
precision medicine and drug discovery.
vi
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With the emergence of sequencing techniques and later high throughput techniques such as mi­
croarray and next­generation sequencing (NGS) [1], biomedical studies are partially liberated from
the limited availability of data. As a result, the demand for modern computational methods to inter­
pret the increasingly massive data is triggered. It is evident that biology is set to become a highly
quantitative science instead of a basic qualitative descriptive one. Therefore, computational biol­
ogy came into being. According to the National Institute of Health (NIH), computational biology
includes the development and application of data­analytical and theoretical methods, mathematical
modeling and computational simulation approaches to the study of biological, behavioral, and social
systems [2].
Due to the inherent complexity within biological systems, it is obvious that hand hard­coded
methods can seldom get the analysis done effectively. That’s when learning based approaches came
into play. Machine learning has the capability of discovering hidden patterns and constructing pre­
dictive models without making strict assumptions in advance. Thus, it has become one of the major
players in computational biology. Despite a wide spread of successful computational biology appli­
cations, the performance of most machine learning methods is empirically shown to be highly depen­
dent on the data representations or features used. In practice, much of the efforts in deploying ma­
chine learning methods go to the feature designs. Initially, features are usually knowledge­based and
engineered by domain experts through years of trial and error. Such a process is generally considered
as feature engineering, In the early days, when the scale and diversity of biomedical data were still
relatively limited, to take advantage of human­prior knowledge is a great way to improve the inter­
pretability and generality of learned biological models as well as to guarantee the initial successful
applications of machine learning in biomedical studies. However, when faced with more diverse data
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as we have nowadays, feature engineering approaches are not sufficient to support satisfactory work.
Firstly, the complexity of the data will make the existing domain knowledge inadequate. Secondly,
the scale of the data could merely make the labor required in manual feature engineering unaccept­
able.
Therefore, to expand the scope and ease the applicability of machine learning, it would be
highly desirable to make learning algorithms less dependent on feature engineering and come up
with an automated process that can learn ”good” features itself ­ representation learning or feature
learning rooted from such growing realization. Generally speaking, representation learning is a set of
techniques that learn data transformation that converts raw data input into a new feature space where
the information can be somehow more easily and effectively exploited in machine learning tasks.
Representation learning obviates manual feature engineering and allows a machine to both learn at
a specific task (using features) and learn the features themselves (to learn how to learn). Although
”What is a good representation” or a common objective for representation learning is not yet estab­
lished, learned representations are generally expected to be capable of identifying and disentangling
the underlying explanatory factors hidden in the observed low­level sensory data and facilitate the
following supervised or reinforcement learning tasks [3]. In addition to the focus of downstream ma­
chine learning task performance in the design of feature learning methods, a common strategy used
in representation learning is to explicitly inject some clues or prior assumptions over the learned rep­
resentations to help guide the learning process. Here we summarized some examples of priors that
could be generally helpful for representation learning.
• Manifolds (or lower dimensionality): real­world data presented in high­dimensional data
spaces are likely to concentrate on the vicinity of a manifold M of much lower dimensional­
ity, embedded in a high­dimensional space where the data lives. Also, a lower­dimensional
representation is preferred since it can be helpful to alleviate the high dimensionality curse.
• Disentanglement of explanatory factors: observations are assumed to be generated by multi­
ple underlying explanatory factors of variation and the dependencies on such factors should
be simple, typically linear dependencies. More preferably, the factors are statistically uncorre­
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lated or independent from each other.
• Distributed representation: the representation learned is expected to be expressive, meaning
that a reasonably­sized learned representation should be able to capture a large number of in­
put configurations (concepts). Distributed representation is the most typical way to achieve
such expressiveness, which offers exponential gains over more local approaches such as one­
hot representation. Specifically, within a distributed representation, k out of N representation
elements or features values can be independently varied, and the combinatorial value of such
k features are used to represent concepts. In addition, each representation element can be in­
volved in representing multiple concepts.
• Sparse representation: A special case of distributed representation, where k is required to be
strictly smaller than N , which means that for any given input configuration, only a small frac­
tion of the possible is relevant. In terms of representations, this could be demonstrated by fea­
tures that are often zero, or by the fact that most of the extracted features are insensitive to
small variations of input.
• Hierarchical organization of explanatory factors: the concepts that are useful for describing
the world often can be defined by other concepts in the hierarchy, with more abstract concepts
higher in the hierarchy, defined in terms of less abstract concepts.
Just like almost all other kinds of data, data with comprehensive or accurate annotations (la­
bels) in biomedical studies are still relatively limited and often expensive to obtain, and in such sce­
narios, generalizable supervised learning is not always possible. Hence, to achieve successful ma­
chine learning applications in this area requires us to devise proper approaches to leverage the more
abundant unlabeled data. Such needs increased the necessity of unsupervised representation learning
methods, which gained its revamped popularity along with deep learning, which offers a promising
solution to make good use of unlabeled data in an unsupervised, semi­supervised or more recently
self­supervised manner. In particular, unsupervised representation learning is aiming to uncover the
hidden structure of the data at hand, and then use the learned transformation (encoding process) to
help boost other tasks’ performance. In particular, a consistent scheme of these methods is that they
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Figure 1.1: Example of Hiearchical Multiple Levels of Omics Data. Figure appeared in [9].
construct a low­dimensional space from the unlabeled raw datasets, and then leverage the learned
low­dimensional embedding explicitly or implicitly for diverse downstream supervised tasks. This
popular approach ,pre­training fine­tuning approach, originated from the work [4] where a detailed
discussion on the benefits of pre­training is given and has gradually gained more and more attention
with the effective applications in both computer vision studies such as [5, 6] and natural language
processing tasks such as [7, 8]. Though sharing some commonalities, the complex and heteroge­
neous nature of biomedical data requires us to actively adapt and devise innovative representation
learning methods that tailor to the organization and specifics of biomedical data in addition to the
aforementioned feature learning generic priors and successful applications in other areas. And ul­
timately we could present biologically meaningful representation learning frameworks that would
benefit miscellaneous downstream tasks of biological and clinical interests.
In particular, to comprehensively understand human health and diseases requires interpretation
of molecular intricacy and variations at multiple levels of the hierarchical biological system, such as
genome, epigenome, transcriptome, proteome and metabolome [10] as shown in Figure 1.1. With
the advancement of high­throughput sequencing techniques, we have been able to generate and col­
lect data at these levels, which together is called as ”multi­omics” data. Informally, the word ‘omics’
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Figure 1.2: Example of Multi­Omics Data Repositories. Figure appeared in [10].
refers to a field of study in biology ending in ­omics, such as genomics, transcriptomics, proteomics
or metabolomics, which reflects their corresponding study objects, such as the genome, transcrip­
tome, proteome, and metabolome of organisms, respectively. Omics aims at collectively character­
ing and quantifying miscellaneous biological molecules that translate into structure, function, and
dynamics of organisms. Different omics data capture different perspectives of a biological system.
Some of the notable data repositories for multi­omics data are listed in Figure 1.2.
Such abundance and diversity of omics data have enlarged the possibility of finding solutions
to more biological problems. Take transcriptomics data as an example, transcriptomics is a powerful
technique to characterize cellular activity under various conditions, allowing researchers to uncover
the underlying associations among genes, biological pathways, diseases, and environmental factors.
Hence, this data source has been widely explored by studies ranging from regulatory gene identifica­
tion [11, 12] to disease biomarker discovery [13]. Further, the emergence of pharmacogenomics data
[14], which records cell lines’ multi­omics profiles and their drug responses against a range of drug
agents provide exciting rich data resources for development of personalized medicine, such as in [15,
16]. Despite the rich data sources and promising prospective brought by multi­omics data, there are
several major challenges in delivering successful multi­omics data integration and followingly con­
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struct practical useful predictive models. Firstly, the complex nature of the biological system and
lack of ”fundamental biological principles” result in the absences of generic guidelines of formaliz­
ing biological problems. Secondly, the inherent heterogeneity of multi­omics data due to the increas­
ing diversity of experimental techniques make integration of multi­omics data very difficult if not
impossible. Thirdly, due to biological variability and precision limits, raw multi­omics data is often
full of noise. Last but not least, multi­omics data analysis is a sufferer of high dimension curse, due
to the data’s high­dimensionality and relatively small sample quantity, especially samples with co­
herent annotations. On the one hand, the high­dimensionality of data will make the interpretation of
the learned results extremely difficult; on the other hand, it will also make it problematic to achieve a
statistically significant result. Hence, it would be beneficial to explicitly explore available representa­
tion learning methods and develop new methods to accommodate the ever­increasing needs to better
understand the multi­omics data in practice and thus push the frontier of applying machine learning
methods in biomedical studies.
In my works, I explored the potential usefulness of aforementioned classical pre­training fine­
tuning schemes in leveraging unlabeled data to boost performance of downstream supervised tasks
such as drug sensitivity prediction. In addition, by utilizing the information hidden in the ”natural”
annotations associated with the multi­omics data, we have shown that such information could help
to further improve the feature learning effectiveness and meaningfulness in Cross LEvel Information
Transmission (CLEIT) network and Coherent Cell line­Tissue Deconfounding Autoencoder (CODE­
AE).
In particular, CLEIT aims to leverage the hierarchical relationships among omics data at differ­
ent levels to drive the biologically meaningful representation learning. In addition, due to the infor­
mation transmission from DNA to phenotype involves multiple intermediate levels of RNA, protein,
metabolite, etc. The higher­level features (e.g., gene expression) usually have stronger discriminative
and interpretable power than the lower level features (e.g., somatic mutation). However, in clinical
practice, patients’ mutation profiles are more often directly involved in the selection of therapies.
CLEIT could build effective model that can perform anti­cancer drug response prediction with only
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mutation data.
CODE­AE, on the other hand, aims to learn biologically meaningful representations by explic­
itly de­confounding the con­founding factors such as data source origins. Moreover, due to the lack
of large number of patient samples with drug treatment and response history, most drug response pre­
dictive studies to date have mainly utilized omics profiles from panels of in­vitro cancer cell lines as
input features. However, the model build with in­vitro cell line samples’ applicability in predicting
clinical patients’ response against chosen therapeutic agents is not guaranteed, because of the genetic
and environmental differences between in­vitro cell lines and patient­derived tissue samples and con­
founding factors that may mask intrinsic biological signals. CODE­AE can better extract common
biological signals shared by incoherent in­vitro and in­vivo samples and thus transfer knowledge
learned from cell line data to tissue data while separate confounding factors.
Both CLEIT and CODE­AE explicitly use the ”domain differences” information to guide the
representation learning, thus a wide range of domain adaptation techniques, particularly feature­
based domain adaptation methods are refereed and compared [17].
In summary, I will present an overview of the representation learning methods and feature­
based domain adaptation approaches in Chapter 2, followed by a comparative study on a variety of
autoencoders in drug response prediction task in Chapter 3. In Chapter 4 and Chapter 5, I will detail
the framework of Cross LEvel Information Transmission (CLEIT) network and Coherent Cell line­
Tissue Deconfounding Autoencoder (CODE­AE) and report their respective benchmark performance
against other state­of­art methods. In Chapter 6, I will conclude my dissertation with a summary of




Overview of Representation Learning
Generally speaking, representation learning aims at seeking a transformation of the raw data
that somehow makes it easier to extract information from it when building classifiers or other predic­
tors. The fundamental idea of improving supervised tasks with unsupervised learned features is that
the features useful for unsupervised tasks should be also helpful for the supervised tasks. Throughout
the years, there have been many successful examples. There are two main formalisms of representa­
tion learning methods, namely representation learning as direct mapping, and representation learning
as a probabilistic model.
Representation learning as direct mapping Representation learning can be seen as seeking a
direct mapping procedure that transforms raw input into a new feature space possessing some desired
properties to facilitate follow­on tasks. Mathematically, in its simplest sense, such transformation
could be explicitly parametrized as a function f in the following,
f : x → z (2.1)
where x ∈ Rd stands for raw samples in the original d­dimension space, and z ∈ Rq is the learned
representation of original raw sample. In this case, we can also think f as an encoding function that
encodes the raw data to certain hidden codes. Depending on the formations of f , such mapping pro­
cedures can be categorized into shallow models if no nested functions are involved, or deep model
otherwise. Furthermore, to learn f , an objective function needs to be employed in advance. In the
setting of unsupervised learning, because of the absence of the target labels, objective functions in
use are often a metric that can measure a “distance”­like cost between raw input and new represen­
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tation such as mean squared error in the form of either L(x, z) or L(x, g(z)) ,where g is a decoding
function, or L(z), a direct measurement of the quality of the learned representation. Additional reg­
ularization terms are also commonly included in the objective functions to explicitly or implicitly
demonstrate the prior knowledge or preference over the model.
Representation learning as probabilistic modeling Different from direct mapping, where
the observations are directly encoded into another representation, representation learning can be for­
malized as a probabilistic model, where typically a list of latent variables are involved. The latent
variables are assumed to be underlying explanatory factors of variation that generated the data. From
the probabilistic modeling perspective, the question of representation learning can be interpreted as
an attempt to recover a parsimonious set of latent random variables that describe the most probable
distribution over the observed data [18]. Under this framework, it is fundamentally assumed that the
responses on the observed variables are the results of different configurations over the latent vari­
ables.
Formally, we can express such framework as an attempt to model the joint distribution of ob­
served variables and latent variables, i.e.,P (x, z), where x is a vector of observed variables in space
X (∈ Rd) and z is the vector of latent variables in the space Z from which we can easily sample
from some prior probability density function (PDF) P (z) over Z ∈ Rq. Typically, the model can be
learned by estimating a set of model parameters that maximize the likelihood of the training data, the
likelihood of one particular training sample can be calculated as,
P (x) =
∫
P (x|z)P (z)dz (2.2)
Similar to direct mapping, additional regularization constraints can also be added to further guide the
training. The feature learning process can then be conceived as the inference process to determine
the posterior probability distribution of the latent variables given the observations (or realizations of
observed variables), i.e., P (z|x). Last but not least, a posterior distribution over latent variable is not
yet a simple, usable feature vector that can be fed into following tasks, and actual values for the new
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features need to be further derived from that distribution, for example, taking the latent variable’s
expectation.
In summary, representation learning is all about to learn a new representation of the raw input
so that the desired properties possessed by the new representation can facilitate follow­on tasks. The
apparent advantage of formalizing representation learning as mapping is simple and straightforward,
yet how to interpret the learned representation properly is very challenging. On the other hand, from
the probabilistic modeling perspective, we could have a straightforward interpretation of the new
representation learned since the latent variables could be naturally associated with the explanatory
factors. Yet the legibility and usefulness of learned latent variables as well as the optimization in­
volved could be very challenging. Thus, I will interpret the following representative feature learning
methods from two perspectives if appropriate. Further, the idea of representation learning or feature
learning has existed for decades, yet the popularity gained in recent years is primarily due to the re­
naissance of deep learning methods. To distinguish the deep learning­based saints from others, I will
thus split the methods reviewed here into two main categories, shallow and deep model.
Shallow model based representation learning methods
Classical shallow model based representation learning methods include Principle Component
Analysis, Independent Component Analysis and sparse coding, as well as their notable extensions.
PCA
Principal component analysis (PCA) [19, 20] is a statistical procedure that seeks linear combi­
nations of the original variables such that the derived variables could capture the maximal variance
within the data in an orderly fashion. Specifically, PCA uses an orthogonal linear transformation to
project a set of observations of possibly correlated variables into a new space of linearly uncorrelated
variables (called principal components). The transformation is defined in such a way that the first
principal component in the derived space has the largest variance, and each following component,
in turn, has the highest possible variance under the constraint that it is orthogonal to the preceding
components. By definition, the first few principal components possess most of the variance (or statis­
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tical information), thus only first few components will be selected to represent the original data while
preserving as much as “variability” as possible. PCA is primarily used as a dimension reduction and
data exploratory technique. Mathematically, PCA can be formalized as,
X̂ = XW (2.3)
subject toWTW = I and I is the identity matrix.
where X ∈ Rd stands for the raw input. Loading matrixW ∈ Rd, is an orthogonal matrix
responsible for transforming the raw input matrix X into a new d­dimensional representation X̂. Each
column (feature) of the transformed matrix X̂ is called principal component, which essentially is a
linear combination of the original features. As mentioned above, PCA will only keep the first q prin­
cipal components as the new representation of the raw data, correspondingly only the truncated load­
ing matrixWq which only includes the first q loading vectors needs to be constructed. Mathemati­
cally, we can presentWq as,
X̂q = XWq (2.4)
subject toWTq Wq = I and I is the identity matrix.
where X̂q is the new representation, and it can be mathematically proved that X̂q ∈ Rq pre­
served the maximum variance of original data for any given q, while minimized the reconstruction
error defined as following, ∥∥∥X̂WT − X̂qWTq ∥∥∥22 (2.5)
In practice, PCA can be done through either the singular value decomposition of data matrix X (after
column­wise centering) or eigenvalue decomposition of data covariance matrix XTX. PCA is con­
sidered as the optimal orthogonal transformation for obtaining a subspace while preserving most of
the variance in original data. Besides, there is no underlying data distribution assumption required in
PCA, hence making PCA highly adaptable.
Although PCA is probably the oldest and most widely used feature extraction technique and
has been seen as one of the go­to methods when it comes to build benchmark representation learning
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framework, inherently it has certain shortcomings. Firstly, because typically a column­wise center­
ing is required for PCA processing, PCA is highly sensitive to the noise in the data. Robust PCA
[21] decomposes the raw data matrix into two components of same size as original input: a low­rank
component that corresponds to general data pattern and a sparse component corresponds to distur­
bances to alleviate PCA’s sensitivity towards noises. Secondly, transformed features obtained from
PCA are considered as a linear combination of all original variables, if the original variables are in a
high­dimensional space, how to leverage the contributions from raw features is problematic, which
in the end makes the interpretation of learned features very challenging. Sparsity constraints on load­
ing matrix [22, 23] are introduced to make the learned features combinations from a relative small
number of orginal features and thus improved the interpretation power. Moreover, similar to the ker­
nel trick from [24], Kernel PCA [25] were proposed to obtain non­linear principal components and
combat the limited modeling capacity and inability to understand the complex interactions between
any input variables of the original linear PCA. Last but not least, in [26], the authors formalized PCA
as a Gaussian latent variable model and computed principal components via likelihood maximization,
which provided an alternative probabilistic perspective of PCA and improved PCA’s interpretability.
ICA
Independent Component Analysis (ICA), another rich family of feature extraction technique,
is among the oldest representation learning algorithms. ICA learns a linear transformation that could
separate the observed variables into many understandable signals (sources), and these signals are
intended to be fully independent (rather than merely decorrelated from each other) [27]. In the end,
the recovered (learned) sources can be used as the new representation of the raw data. The major
contribution of ICA was the realization that the model can be made identifiable by making the uncon­
ventional assumption of the non­Gaussianity of the independent latent variables (components).
ICA originated as a classical solution to the blind source separation task (BSS) [28] . Consider
random observational variables denoted by xi (t) , i = 1, 2, . . . , d, t = 1, 2, . . . , n, here t is the
index of the observations (or time index in BSS) and d is the index of the observed variables. In ICA
assumes observations can be derived as linear combinations of statistically mutually independent
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latent (hidden) variables zj (t) , j = 1, 2, . . . , q, via some unknown mixing coefficients aij . Without





for all i = 1, 2, . . . , d.
Further if we drop the sample index t, and denote observation variables and latent variables as
vector x ∈ Rd and z ∈ Rq, and then formulate mixing coefficients as a mixing matrix of shape d × q.
Then, ICA model becomes,
x = Az (2.7)
To recover the latent variables z from corresponding observed vector x, we need to first estimate an
un­mixing matrix such that,
ẑ = Wx (2.8)
For simplicity, ICA model assumes mixing matrix A to be square and invertible so that un­mixing
matrixW = A−1. To estimate the un­mixing (mixing) matrix, a specific objective needs to be set up.
As the major breakthrough of ICA, intuitively it was proved [27] that the maximization of the non­
Gaussianity of components can lead to the independent components as desired in ICA model. So,
ICA estimation could be done by adaptively calculating an un­mixing matrix that transforms obser­
vations to independent latent components with the maximization of non­Gaussianity of components
as objective. Common quantitative non­Gaussianity measure includes Kurtosis and Neoentropy. Al­
ternatively, ICA estimation could also be done via the minimization of mutual information among
independent components, or by maximum likelihood estimation when treat ICA as a linear genera­
tive model with non­gaussian independent latent variables. Popular ICA algorithms include FastICA
[29] and Infomax [30].
One of the assumptions in basic ICA is that the number of observed variables should be equal
to the number of sources (latent variables). Obviously, in reality this condition can be not satisfied
always. So, ICA is further split into undercomplete and overcomplete ICAs. Undercomplete ICA,
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stands for the condition that the number of sources is smaller than the number of observed variables.
It can be solved by first applying dimension reduction methods (such as PCA) to transform the ob­
served data to have the same dimensionality as the sources, then standard ICA algorithm can be
adopted to obtain the estimates of the independent sources. On the other hand, overcomplete ICA,
stands for the condition that the number of sources is bigger than the number of observed variables.
Typically, it can be solved by ideas stemming from sparse coding [31]. Notable methods include [32,
33].
Sparse Coding
Similar to ICA, sparse coding also relates a list of latent variables z to the observed variables x
through a linear mapping (W, called dictionary in sparse coding). In addition, sparse coding includes
a penalty to ensure only a sparse activation of z (i.e. one with many features set to exactly zero) is
used to encoder each input x. From a direct mapping perspective, sparse coding can be seen as con­
structing a sparse code associated with the input x via:
z∗ = f(x) = argminz ∥x − Wz∥22 + λ ∥z∥ (2.9)






where x(i) is the i­th example and z∗(i) is the corresponding sparse code calculated the above formula.
Further, to guarantee the identifiability of (W, (W is usually constrained to have unit­form columns.
Alternatively, sparse coding can also be viewed from a probabilistic perspective. Sparse coding uses
a sparsity­inducing Laplacian prior over the sparse codes and can be solved by expectation maxi­
mization algorithm [34].
Spike­and­slap sparse coding (S3C) [35] is one of the variants of sparse coding specialized
in unsupervised feature learning. The S3C model splits the latent variables into two individual set,
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namely, a set of latent binary spike variables , and a set of real­valued slab variables. S3C model
used the set of binary spike variables to explicitly control of the sparsity pattern of latent variables,
while sparse coding place a factorial prior on latent variables such as Laplace distribution to encour­
age the posterior mode to be sparse. Similar to sparse coding, the learning and inference of S3C
model can be done with variational EM algorithm.
Aforementioned PCA, ICA, sparse coding methods have been adopted in high­dimensional
multi­omics data analysis primarily as dimension reduction techniques to support effective statisti­
cal machine learning, such as PCA in [36, 37, 38]. In [39], PCA was applied over the gene expres­
sion data in an attempt to capture the underlying cluster structure. However, due to the statistical
procedural nature of PCA, there are no effective ways to incorporate biological consideration into
the learned representation. For the real­life dataset, it is often the case that the observed data con­
tain many signals mixed up, so ICA is a natural fit to complete the unmixing. For example, a gene
expression level may originate from many biological processes or underlying biological factors. In
most scientific studies, the original signals or processes (or underlying explanatory factors) are ex­
actly the targets we want to recover. ICA then can be used to decompose input data into components
so that each component is statistically as independent from each other as possible and potentially re­
veal the underlying patterns as a result. Notable applications include [40, 41], in which ICA is used
to make effective and accurate detection of gene clustering patterns via statistical analysis of omics
data, and [42, 43] where ICA is used for identification of cancer and oncogenic pathways. However,
the number of ICs to be decided in advance is also a challenging task. Moreover, the biological sig­
nificance of ICs extracted is not guaranteed. Sparse coding is another widely used tool dealing with
high­dimensional data. By incorporating sparse coding and local linear mapping, the authors of [44]
achieved high accuracy in a classification task. In [45], various sparse coding and dictionary learning
models are discussed and compared towards a classification task. Sparse linear modeling of RNA­
Seq data for isoform discovery and abundance estimation SLIDE [46], used a sparse­coding­like
approach to predict the likely position of isoform given RNA­seq data.
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Figure 2.1: Architecture of Standard Autoencoder.
Deep Learning based representation learning methods
Usually, we call a model “deep”, when the model is trying to model a function with an explicit
nested structure. A neural network with more than one hidden layer is considered as a deep model,
which gave birth to the popular idea of “deep learning”. The renaissance of deep learning from 2006
began with the discovery that, greedy layer­wise unsupervised pretraining can be used to find a good
initialization for a joint learning procedure over all the layers [47, 48]. Moreover, the same approach
has been used to train even fully connected architectures successfully. Essentially, each layer of such
hierarchical structure is to learn intermediate­level features. Empirically, it has been observed exten­
sively in many studies [49], the stacking of intermediate features often yields better representations.
Due to the extreme popularity of deep learning in recent years, there have been extensive approaches
proposed, here I focus on only the autoencoders, a well­established technique to learn an encoding
function that maps a high­dimensional vector to a low­dimensional embedding.
Overview of Autoencoders
An autoencoder [50] is a neural network that is trained to learn how copy its input to output.
Typically, it has at least one hidden (intermediate) layer that represents the input with certain codes.
A framework for autoencoder with only one hidden layer h is shown in Figure 2.1, In its simplest
sense, the autoenoder network can be considered as consisting of two parts: an encoder function f
that generates the hidden code for the input, i.e., z = f(x) and a decoder function g that produces the
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output (reconstructed input), i.e., r = g(z). We often call encoder and decoder function as encoder
module and decoder module respectively, since they can be modeled with any neural network archi­
tecture themselves. It is easy to see that the reconstructed input can be represented by a nested func­
tion as r = g(f(x)) . As mentioned above, the purpose for autoencoder is to make the reconstructed
input as similar as possible to the original input (maximize similarity) or, in practice to minimize the






“Distance” (or “Dissimilarity”) measurements like MSE (mean squared error, used for continuous­
valued input), cross­entropy (used for binary valued input) are the commonly used loss functions.
Autoencoders are considered as a special case of feed­forward networks with an unsupervised objec­
tive, thus can be trained with the common techniques applicable to feed­forward networks learning.
However, copying input to output essentially is not an interesting or challenging task. For ex­
ample, if we make f and g inverse functions of each other, then such autoencoder will be able to
achieve exact reconstruction even. In such cases, the autoencoders are not necessarily useful, since
the hidden code doesn’t have to learn the inherent structure underlying the data to get the reconstruc­
tion done. So, more than often, autoencoders are designed to be unable to learn to copy perfectly,
while instead encourage the intermediate codes learned to capture the hidden patterns of the input.
Typically, such autoencoders are restricted in different forms and can be called regularized autoen­
coders.
In the early days, autoencoders were primarily used as dimension reduction technique, to learn
an under­complete representation, where the dimension of the hidden code is specified to be smaller
than the dimension of the input data. In this setting, the dimensionality of the hidden code is used as
the regularization on the autoencoder (called under­complete autoencoder). A special example of the
under­complete autoencoder is one that only linear activation functions are allowed for the encoder
and decoder with the mean squared error being used as the loss function (reconstruction loss). The
representation learned from such autoencoder will span the same subspace as standard PCA, and
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such autoencoder is no different from the standard PCA. The under­complete autoencoder is just
one example of regularized autoencoders. More often, other forms of regularization are included to
explicitly push learned hidden representation towards spefic desired properties as well as ensure the
generalization of autoencoders.
Deterministic Autoencoders
Autoencoders as described above, hidden codes are learned though a fixed mapping defined
by encoder network. Such autoencoders are called deterministic autoencoders. Depending on the
choice of regularization techniques employed, deterministic autoencoders can be further split into the
following categories.
Sparse Autoencoders A sparse autoencoder is an autoencoder whose training objective in­




L(x, r) + Ω(z) (2.12)
Commonly used sparsity penalty terms include L1­norm [51, 52], Student­t penalty (log(1+z2j))[53].
Adding such sparsity penalty intuitively can ensure that only a few input configurations have low
loss. In addition to considering the sparsity penalty as a regularizer for reconstruction task, we could
also think sparse autoencoders from the probabilistic modeling perspective as mentioned in chapter
two, where the hidden codes to be learned is the latent variables that serve as the underlying explana­
tory factors of the realizations of the observed variables. Formally, we can represent the entire sparse






where x is a vector of observed variables in space X ∈ Rd and z is the vector of latent variables in
the space Z ∈ Rq, and Pmodel(z) is the model’s prior distribution over the latent variables that repre­
sents the model’s belief or assumption. Autoencoder can thus be considered as approximating such
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likelihood with a point estimate for one highly likely value for z. But different from sparse coding
model, z will be the output of the parametric encoder rather than the result of an optimization that
aims to infer the MAP value of z. Further, in the context of sparse autoencoder, Pmodel(z) needs to
be sparsity­inducing, for example, the Laplace prior or Student­t prior.
Contractive Autoencoders The contractive autoencoder (CAE) [54] introduces another type of
constraint on the hidden code to push the derivatives of encoder function to be as small as possible,
so that hidden codes capable of resisting input perturbations can be learned. The objective function




L(x, r) + Ω(h) (2.14)





. The penalty Ω(h) the squared Frobenius norm of the Jacobian matrix
of partial derivatives associated with the encoder function. The goal of contractive autoencoders is
to make the encoder to resist infinitesimal perturbations of the input while not sacrificing too much
in terms of the reconstruction loss, so that the hidden codes learned could potentially capture more
of the inherent patterns underlying the input data. By doing so, CAE is encouraged to map a local
neighborhood of input points to a smaller neighborhood of output points (input reconstructions), as
the name suggests – contracting neighborhoods. The learned representations can be thought of as a
manifold structure of the data, where the directions of observed variables leading in large changes in
latent variables could approximately correspond to the tangent planes of a manifold.
Two practical issues with CAEs need to be pointed out, though. Firstly, although it is relatively
cheap to compute the contractive penalty when the encoder network only includes one single hidden
layer, computation will become significantly higher when the encoder network becomes deeper. One
solution proposed in [54] is to separately train a series of single layer autoencoders instead train all
layers at the same time. Each of them is trained to reconstruct the output of the previous autoencoder.
Then the composition of the autoencoders is used as the final model. Yet this model is not the same
as what would be obtained by jointly training the entire deep architecture with a penalty on the Jaco­
bian of a deep encoder network. Secondly, there have to be some capacity constraints on the decoder
network, such as tying the parameters of encoder and decoder network. Otherwise, the decoder could
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potentially adapt to compensate the contractive regularization on the encoder network and result in
useless hidden representation being learned.
Denoising Autoencoders Rather than adding penalty terms to the cost functions, denoising
autoencoder attempts to minimize the reconstruction cost with the input corrupted by some form of
noise [55]. The goal of denoising autoencoders is to make the reconstruction function resist small but
finite­sized perturbations of the input. Denoising autoencoders (DAE) thus have to be able to undo
the corruption rather than copy their corrupted input. In other words, the encoder and decoder are






where x̃ is the corrupted input. From a probabilistic modeling perspective, DAE aims to learn a re­
construction distribution Preconstruct (x|x̃) = Pdecoder (x|f(x̃)) estimated from training pairs (x, x̃),
where x̃ follow certain corruption process and Pdecoder defined by the decoder network. Thus, we can
further view DAE as performing maximum likelihood learning of Pdecoder (x|f(x̃)). Besides max­
imum likelihood optimization, score matching [56] can also be used as an alternative approach to
train DAE model, where probability distributions are estimated by encouraging the model to have
same scores as the data distribution (empirical distribution of the data) at every training data point.
Specifically, for DAE training, the score to be used is ∇xlogP (x). DAEs are also an example of how
over­complete, high­capacity models may be used as autoencoders so long as care is taken to prevent
them from learning the identity function.
Stochastic Autoencoders
Different from deterministic autoencoders, where the hidden representations are learned via
the fixed mapping defined by the encoder network from the raw input, modern autoencoders have
generalized the idea of an encoder and a decoder from deterministic functions to stochastic mappings.
With respect to the formation of stochastic autoencoder, its encoder network can parametrize an en­
coding distribution Pencoder(z|x), from which we can sample hidden codes given an observation of x.
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Figure 2.2: Architecture of Stochastic Autoencoder.
Similarly, the decoder network is used to parametrize a decoding distribution of Pdecoder(x|z). Then
given a hidden code z, with prior z ∼ P (z), we could train the entire autoencoder by maximizing
the marginal likelihood (log­likelihood) of the training data. A general framework of the stochastic
autoencoder is shown in Figure 2.2, In this setting, to obtain the latent representation given observa­
tions, an inference process is needed, or true posterior P (z|x) needs to be estimated. By Bayes rules,
we can get,
P (z|x) = P (x|z)P (z)
P (x)
(2.16)
Thus, to get the inference from observed variables to latent variable, P (x) =
∫
P (x|z)P (z)dz needs
to be calculated, however, it is easy to see that this integral requires exponential time to compute
since it needs to be evaluated over all configurations of latent variables. Thus, efficient approxima­
tion of posterior needs to be done.
Variational Autoencoders Variational inference approximates the true posterior with a fam­
ily of parametric distributions with Kullback­Leibler divergence (KL divergence) used as the mea­
surement of the approximation quality. And the optimal approximate posterior is the one that mini­
mizes the KL­divergence from true posterior P (z|x). Variational autoencoder (VAE) [40] adopted
this idea and proposed to use a network architecture to parametrize such approximate posterior (i.e.,
Pencoder(z|x)). The KL divergence between approximate posterior and ground­truth posterior is
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given below,
DKL(Pencoder(z|x)||P (z|x)) = Ez∼Pencoder(z|x)[logPencoder(z|x) − logP (z|x)]
= Ez∼Pencoder(z|x)[logPencoder(z|x) − logP (x|z) − logP (z)] + logP (x)
(2.17)
we can get,
logP (x) − DKL(Pencoder(z|x)||P (z|x)) = Ez∼Pencoder(z|x)[logP (x|z) + logP (z) − logPencoder(z|x)]
(2.18)
Up to this point, the left­hand side of above equation is the quantity to be maximized, including the
maximization of the marginal likelihood of observation as well as the minimization of non­negative
KL­divergence between true posterior and approximate posterior. The right­hand side can be fur­
ther reduced to Ez∼Pencoder(z|x)[logP (x|z)] − DKL(Pencoder(z|x)||P (z)), which is a tractable quan­
tity and can be optimized via standard stochastic gradient descent. It is also called ELBO (Evidence
Lower BOund) and used as the training objective of variational autoencoders, denoted here as LV AE .
Specifically, P (z) is the prior over latent variables, typically z ∼ N(z; 0, I). P (x|z) can be mod­
eled by the decoder (i.e., Pdecoder(x|z)). Depending on the characteristics of input data, it could be
assumed to follow different known distributions, such as Gaussian distribution for continuous­valued
data, and Bernoulli distribution for binary­valued data. As for Pencoder (z|x), the usual choice is
N(µ, Σ), where µ, Σ are to be determined by the encoder network, and Σ is normally constrained
to be a diagonal matrix. The parameters of both encoder and decoder network can be learned by max­
imizing the ELBO. In practice, the re­parametrization trick is also employed to ensure the stochas­
ticity of the model while keeping gradient descent applicable in the training process. The variational
autoencoder is theoretically elegant and capable of achieving state­of­the­art generative modeling
result [57]. Moreover, it is very simple and straightforward to implement and supports a wide range
of extensions. Notable examples include importance weighted variational autoencoder [58], β­VAE
[59], Factor VAE [60], and InfoVAE [61].
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Adversarial Autoencoders Adversarial autoencoders (AAE) [62] is another type of stochastic
autoencoder which incorporates generative adversarial networks (GAN) [63] to perform variational
inference by matching the aggregated posterior of the hidden code vector of the autoencoder with an
arbitrary prior distribution. In the framework of standard generative adversarial network, a min­max
adversarial game is established between two neural nets – a generator network G and a discrimina­
tor network D. The network D aims to distinguish samples of training data (x ∼ Pdata) from the
samples produced by the generator network G from ẑ ∼ P (ẑ), while generator network G tries to
confuse discriminator D as much as possible by imitating the true data. The solution to this game
can be formally expressed as
minGmaxDEx∼Pdata [logD(x)] + Eẑ∼P (ẑ)[log(1 − D(G(ẑ)))] (2.19)
In AAE, the encoder network is used as the generator to make hidden codes (z) mapped from the
input (x ∼ Pdata) as similar as possible to ẑ ∼ P (ẑ), here P (ẑ) stands for the prior distribution
we desire to impose on the codes. The encoder of AAE Pencoder (z|x) is used to define an aggregated
posterior distribution of Pencoder(z) on the hidden codes as follows:
pencoder(z) =
∫
Pencoder (z|x) Pdata(x) (2.20)
The adversarial autoencoder is regularized by matching Pencoder (z) to P (ẑ). Similar to original
GAN, the training of AAE needs to be done alternatively between the reconstruction loss and dis­
criminator loss. Here, Pencoder (z|x) can be assumed to be deterministic mapping of observations
as standard autoencoder as well as follow a Gaussian distribution as in VAE where the same re­
parametrization trick needs to be employed. A brief architecture of AAE is given in Figure 2.3,
Similar to AAE, adversarial regularized autoencoders (ARAE) [64] also includes a GAN mod­
ule in the architecture. From Figure 2.4, different from AAE, a complete GAN architecture is incor­
porated in ARAE. In ARAE, the hidden codes mapped from the input data via encoder network are
used as the positive samples to the GAN module. In contrast to AAE, the training of ARAE also in­
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Figure 2.3: Architecture of Adversarial Autoencoder.
Figure 2.4: Architecture of Adversarial Regularized Autoencoder.
cludes the generator that maps random noise ẑ ∼ N(ẑ; 0, I) to approximate the hidden codes of
autoencoder.
When it comes to applications of autoencoder­based representation learning in biomedical
studies, to deal with the high­dimensionality concern of the omics data, apparently, under­complete
auto­encoder is an obvious choice. Besides the high­dimensionality concern, the reliability of cross­
experiment datasets is limited by the technical noise and unmatched experimental conditions. Of­
ten, denoising and enhancement of the available data are necessary. A useful tool for this scenario is
denoising autoencoders. In [65], stacked denoising autoencoders (SDA) are applied to detect func­
tional features from the cancer gene expression profile. [11] presented an unsupervised approach
that effectively applied SDA to capture key biological principles in breast cancer data. [66] further
improved ADAGE to extract both clinical and molecular features successfully. To build better signa­
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tures that are more consistent with biological pathways and enhance model robustness, an ensemble
ADAGE [67] was proposed to integrate stable signatures across models. Besides, [68] first utilized
multi­layer denoising autoencoders to enhance yeast expression microarray data, and then success­
fully identified cell cycle process through a following clustering task. [69] proposed a four­layered
autoencoder network with sparsity regularization, in which each layer is accounting for a specific bio­
logical process in gene expression to explicitly model the hierarchical organization of transcriptomic
machinery. Recent works focused more on the application of variational autoencoders, which seems
more promising at capturing the internal dependencies among data. [70] trained VAE­based models
to reveal the underlying patterns in the pathways of gene expression and compared their three VAE
architectures to other dimensionality reduction techniques. The same group of authors later proposed
[71], when they trained a VAE on The Cancer Genome Atlas (TCGA) pan­cancer RNA­seq data to
uncover biologically­relevant features. [72] introduced the DeepProfile, a framework featuring VAE,
to extract latent variables that are predictive for acute myeloid leukemia from expression data. [73]
proposed Deep Genomic Signature (DGS), a pair of VAEs that are trained over unlabeled and labeled
data separately from expression data for predicting metastasis.
To sum up, miscellaneous unsupervised representation learning approaches have been pro­
posed. Yet, it remains an open question to pick the best overall unsupervised representation learning.
To put them into practice, innovative adaptations tailored to specific datasets and problems at hand
are still much needed.
Overview of Feature Based Domain Adaptation
Although supervised learning is arguably the most popular type of machine learning and has
enjoyed success across diverse application areas, the majority of them rely on one common assump­
tion: the training and testing data are drawn from the same distribution. When the assumption is vio­
lated, the model will experience a performance decline due to the domain differences. Domain adap­
tation methods are thus proposed to alleviate this dilemma. Specifically, domain adaptation aims at
transferring the knowledge a trained predictive model has gained on one data domain with sufficient
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labeled data to another data domain without or with limited labeled data. Here, a data domain can be
denoted as D as D = {X , P (X)}, where X stands for the feature space and samples within domain
D, X = {x1, . . . , xn} ∈ X . P (X) is the affiliated marginal distribution. In the classical setting of
domain adaptation, we consider two domains, namely source domain DS = {Xs, Ps(Xs)} and target
domain Dt = {Xt, Pt(Xt)}. And there are abundant labeled samples from source domain for one
common predictive task τ of interests, while only limited or none labeled sample of target domain
for the same task. The ultimate goal is to perform accurate predictive task of interest τ based on tar­
get domain data, by transferring knowledge possessed in source domain labeled data. Because of its
ability to adapt labeled data for use in a new application, domain adaptation can reduce the need for
costly labeled data in the target domain.
Most of recent domain adaptation methods align source and target domains by creating a do­
main invariant feature representation, typically in the form of a feature extractor neural network.
A feature representation is considered domain invariant if the features follow the same distribution
regardless of the data from the source or target domain. These models generally assume the exis­
tence of such feature space and the marginal label distributions of task τ do not differ significantly
among the domains. Given a predictor performs well with the domain invariant features in the source
domain, the same predictor is expected to generalize well in the target domain. A general invariant
feature based domain adaptation learning framework is shown in Figure 2.5. Under this framework,
samples from both domains in their respective feature space first go through a feature encoder net­
work. The feature encoder networks for different domains could share weights, share similar regu­
larization or non­related. Then via additional feature alignment component, encoded features from
boths domain are further aligned to be domain­invariant. From the learnt domain invariant feature,
additional task predictor is trained with source domain labeled ata to maintain this trait space’s dis­
criminative power for specific tasks. In addition to choices made on weight/regularization sharing
for domain feature encoders, methods generally differ in the design of feature alignment component.
In particular, it could be either in the form of distribution discrepancy measurement minimization,
adversarial or reconstruction training optimization.
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Figure 2.5: General framework for feature­based domain adaptation methods.
Discrepancy­based domain invariant feature learning
Common choices for distribution discrepancy measurement include maximum mean discrep­
ancy, correlation alignment, and Wasserstein distance.
Maximum Mean DiscrepancyMaximum Mean Discrepancy (MMD) ([74]) is a distance mea­
sure between distributions P (X) and Q(Y ) which is defined as the squared distance between their
embeddings in the RKHS (Reproducing Kernel Hilbert Space, [75]). Given Nx samples from P (X),

















where κ is a PSD kernel function. It can be proven that MMD is zero if and only if the two distribu­
tions are equal. Deep domain confusion network [76], originally designed for classification task for
unlabeled target domain images, as shown in Figure 2.6, adopts weight sharing feature encoder (as
stacked convolution and full­connected layers) across labeled source and unlabeled target domains,
and trains the whole network via a weighted combination of MMD distance between source and tar­
get domain encoded features and classification loss to achieve domain transfer. Moreover, multiple­
kernel variant of MMD (MK­MMD) and joint MMD were investigated in [77] and [78] respectively.
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Figure 2.6: Architecture of Deep Domain Confusion network. Figure appeared in [76].
CORrelation ALignment CORrelation ALignment (CORAL) [79] aligns the input feature
space of the source and target domains by minimizing the difference between their second­order
statistics. To achieve such minimization, in the original CORAL [79], a linear transformation A is
applied to the original features and use the Frobenius norm as the matrix distance metric,
minA
∥∥∥AT CsA − Ct∥∥∥2
F
(2.22)
where Cs and Ct are the co­variance matrices for source and target features respectively. Later, it
was extended to work with deep neural network [80], where CORAL loss is similarly formulated as
above among encoded features of source and target domain samples. And the overall architecture
is similar to the architecture of DDC [76] in Figure 2.6, the only difference is that Deep CORAL
employs CORAL loss in place of the MMD loss and trains the whole network via a weighted combi­
nation of CORAL loss and supervised loss.
Wasserstein DistanceWasserstein Distance originates from a problem know as ”optimal trans­
Chapter 2: Method Review 29
port”, where resource allocation such as finding an optimal way to move materials from mines to
factories are studied. If the moving cost is a norm, then the solution to a discrete optimal transport
problem can be used a discrepancy measurement between distributions. Joint distribution optimal
transport (JDOT) [81] and its neural network extension DeepJDOT [82] were proposed with such
realization. The overall architecture used by DeepJDOT is also similar to the one used in DDC[76],
while the dicrepancy is measured with the Wasserstein distances shown below,
∥Hs − Ht∥2 (2.23)
where Hs and Ht stand for the encoded features through a shared feature encoder of source and tar­
get samples respectively.
Adversarial training based domain invariant feature learning
Most of methods belonging to this category employs a domain classification module in the
feature alignment component. The domain classification module aims to distinguish samples from
source domain from target domain, while the feature extractors aims to generate features that can
confuse this domain classification module into wrong prediction. A min­max game is formulated
between the them to learn the domain invariant features. In domain adversarial neural network
(DANN, [83]), as shown in Figure 2.7. A shared feature extractor is adopted, and the domain classi­
Figure 2.7: Architecture of Domain Adversarial Neural Network. Figure appeared in [83]
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Figure 2.8: Architecture of Adversarial Discriminative Domain Adaptation. Figure appeared in [84]
fier outputs the binary domain label (namely, source or target domain) based on the encoded features.
DANN inserts a gradient reversal layer between the feature encoder and domain classifier, which
will negate the domain classification loss gradient sent to feature encoder in the back­propagation
process. DANN attempts to learn the feature encoder that maps the original samples from both
domains into a feature space that allows accurate task prediction performance with labeled source
samples, while cripples the ability of domain classifier to precisely distinguish samples from source
domain to target domain in the form of binary cross entropy.
In adversarial discriminative domain adaptation neural networks (ADAA, [84]), as shown in
Figure 2.8. ADAA splits the overall training process into three steps, namely pre­training, adversar­
ial adaptation and testing. During the pre­training, a feature encoder and task predictor are trained
for source domain labeled sample with the supervised task. Then, in the adversarial adaptation step,
a generative adversarial neural network [85] is incorporated. The feature encoder for the target do­
main samples are trained such that the discrimator of GAN cannot reliably distinguish the encoded
features from their domain origin. In the final testing step, the trained target feature encoder and the
task predictor in combination are used to complete the inference step.
Moreover, WDGRL [86], Wassertein distance guided representation learning for domain adap­
tation, replaced domain classifier with a Wassertein Generative Adversarial Network [87] to learn the
domain invariant features.
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Figure 2.9: Architecture eof Domain Separation Network. Figure appeared in [89]
Reconstruction based domain invariant feature learning
Reconstruction based domain invariant feature feature learning was proposed under the as­
sumption that feature alignment can be achieved by learning a representation that can be used to re­
construct target domain samples [88] or both the source and target domain data [89], as well as sup­
port predictive modeling of label source domain samples. These methods incorporate autoencoder
components for the reconstruction of input samples. Representative works include deep reconstruc­
tion classification network [88], marginalized denoising autoencoder [90], multi­task autoencoders
[91]. Moreover, domain separation network [89] was proposed to explicitly split domain­specific pri­
vate representations and domain­invariant shared representation. Its architecture is shown in Figure
2.9. The shared feature encoder aims to learn shared representation that contains common transfer­
able information while private encoders learn the domain­specific private representation. The con­
catenations of private and representations are expected to complete the reconstruction task. And the
private and shared representations of each individual domain are pushed apart with a soft orthogonal­
ity loss. Shared representations across domains are further trained with discrepancy minimization or
adversarial training objective in addition to shared feature encoder network. Further shared represen­
tation of labeled source domain samples are further adapted to possess predictive power of tasks of
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interests.
In summary, the aforementioned feature­based domain adaptation methods offer various
approaches that can be utilized to transfer knowledge from one domain to another. Given proper
biomedical datasets and understanding of fundamental relationship between different data entities,
they can be adopted to encourage biological meaningful representation learning.
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Chapter 3
Comparative Study of Autoencoders
Introduction
Due to the heterogeneity among cell lines (tumors), the accurate prediction of drug response
over cell lines (tumors) remains a challenging task. Pharmacogenomics [92] is a field that studys
how genomic alternations and transcriptomics affect drug. In this benchmark study, we aim to uti­
lize the transcriptomic profiles of cell line samples to predict individual drug responses. The drug­
sensitivity data as well as cell lines transciptomic profiles can be obtained from public pharmacoge­
nomics data repository, such as Cancer Cell Line Encyclopedia (CCLE, [15]), and GDSC [93, 94].
However, with only hundreds of available labeled samples, obviously, it is very difficult to build a
generalizable model capable of generating accurate predictions of drug responses. We seek effective
ways to leverage more available unlabeled transcriptomics dataset. In particular, in this benchmark
study, we aims to compare the various autoencoders’ performance (reviewed in Chapter 2) in terms
of their effectiveness in assisting drug­sensitivity prediction task. The overall training paradigm of
this benchmark study is shown in Figure 3.1.
Experiment Setup
As mentioned above, the drug­sensitivity data were obtained from GDSC [93, 94], and cell
lines transciptomic profiles were downloaded from Cancer Cell Line Encyclopedia (CCLE, [15]).
After missing value imputation, we collected a dataset consists of drug sensitivity scores (real­
valued) of 610 cell lines against 205 drugs. For additional unlabeled transcriptomic profiles (gene
expression), we downloaded cancer patient tumor sample gene expression data from the Cancer
Genome Atlas (TCGA, [95]). Firstly, we converted the normalized FPKM gene expression values
through log2 transformation, then genes with low information burden (mean value < 1 or standard
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Figure 3.1: The autoencoder benchmark study training includes two steps: 1)Pre­train the encoder with
autoencoder reconstruction task using unlabeled data. 2)Fine­tune the encoder and appended regressor network
with supervised drug response prediction task using labeled data.
deviation < 0.5) were filtered out. Further, we selected 5000 genes with the highest variability
meansured by median absolute deviation (MAD) as the raw input features. In total, we have 11351
gene expression samples (including 10332 TCGA sample, and 1019 CCLE cell line samples of
which 610 are with labels). We adopted pre­training fine­tuning procedure as shown in Figure 3.1,
in pre­training, we trained the encoder with unlabeled transciptomics data, and during fine­tuning,
additional regressor module were appended after pre­trained encoders to complete drug sensitivity
prediction task. All autoencoders shared the exactly the same architecture [1024, 512, 256, 128, 256,
512, 1024], and the hidden dimension is specified as 128. Appended regressor network shares the
same architecture [128,128] with the number of output units set as the same as number of drugs in
consideration (i.e. 205).
Result & Discussion
Since our primary goal in this benchmark study is to compare the efficacy of different autoen­
coders in this drug response prediction task, we designed the following metric as the final measure­
ment. For any given drug­cell line pair, we will rank predictions from different auto­encoders based
on their absolute value difference from the ground truth value. And the autoencoder obtained the
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smallest difference will be ranked first, and so on so forth. As our final result, we will demonstrate
the percentages of different autoencoder acquired in the top three ranks. The result is listed in Table
3.1.
Method RANK1 RANK2 RANK3
Standard AE 14.82% 13.03% 11.97%
DAE (Gaussian Noise) 18.18% 19.06% 17.86%
DAE (Missing) 17.11% 16.95% 16.21%
CAE 0.99% 1.93% 7.04%
VAE 18.01% 17.08% 15.87%
beta­VAE 10.94% 10.04% 10.13%
InfoVAE 9.85% 10.96% 10.09%
ARAE 1.98% 2.99% 2.87%
Stacked DAE 8.11% 7.98% 7.97%
Table 3.1: Benchmark Performance Comparison among Autoencoders
As seen from our autoencoder comparison benchmark study results, it is hard to draw concrete
conclusions which architecture is superior to others. And even more interestingly, two of the variants
of popular variational autoencoders, beta­VAE and info­VAE cannot beat its original versions or even
standard autoencoder in the drug­response task given in our study. It may be due to that beta­VAE
and info­VAE are primarily designed for the representation disentanglement. while gene­gene inter­
actions are essential characteristics of a biological system, and critical for drug responses. In certain
sense, the results demonstrated the difficulty in applying such new deep models in biological studies
domain. Without any doubt, to properly leverage the strength of popular deep model­based represen­
tation learning methods in omics data studies remains a challenging task, considering the fact that
we only have limited abilities to interpret the biological information compared to other fields, such
as vision, audio, and language processing, as well as the endeavor involved to tune a deep model. To
fully realize its potential and further drive the constant progress in biomedical studies, innovations
such as a more efficient learning scheme or new network architectures based on biologically inspired
inductive bias are still in much needs.
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Chapter 4
Cross­LEvel Information Transmission (CLEIT) network
Introduction
Advances in next­generation sequencing have generated abundant and diverse omics data.
They provide us with unparalleled opportunities to reveal the secrets of biology. An unsolved prob­
lem in biology is how to predict observable traits (phenotypes) given a new genetic constitution
(genotype) under environmental perturbations. The predictive modeling of genotype­phenotype as­
sociations will answer not only fundamental questions in biology but also address urgent needs in
bio­medicine. A typical application is anti­cancer personalized medicine. Given a new cancer pa­
tient’s genetic information, what is the best existing drug to treat this patient? It is different from
Genome­Wide Association Study (GWAS) and Transcriptome Wide Association Study (TWAS),
whose goal is to identify statistical correlations between observed genotype and phenotype. Predict­
ing phenotype from a new genotype is challenging due to the asymmetrical multi­level hierarchical
organization of the biological system. Cell­, tissue­, and organism­level phenotypes do not arise di­
rectly from DNAs but hierarchically through multiple intermediate molecular or cellular phenotypes
characterized by protein interactions, gene expressions, etc. [96], as illustrated in Figure 4.1. In other
words, in the information transmission process from DNA to RNA to protein to a biological pathway
to the observed phenotype of interest, the higher­level features (e.g., gene expression) usually have
stronger discriminative and interpretable power than the lower level features (e.g., somatic muta­
tion) in a supervised learning task for predicting the phenotype, which is independent on the machine
learning model applied. This premise is supported by multiple studies such as anti­cancer drug sen­
sitivity prediction [97], cancer drug combination [98], microbiome [99], and empirical studies [100].
Therefore, a multi­level approach is needed to simulate the asymmetrical hierarchical information
transmission process for linking the genotype to the phenotype [101], which will, in turn, improve
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Figure 4.1: Rationale of CLEIT. Cellular phenotypes rise from genotypes via multi­level intermediate
molecular types hierarchically from DNA to RNA to protein to biological pathway (blue arrows). The
predictive and interpretable power of the DNA­level features for the phenotype is weaker than that of the
high­level features such as transcriptome and biological pathways. Instead of predicting the phenotype from
the genotype directly by bypassing the intermediate molecular types (gray dashed arrow), we will include the
information of intermediate molecular type and model the hierarchical organization of a biology system
(orange solid arrows).
the interpretability of model predictions and facilitate clinical decisions. The interpretability of ma­
chine learning model is critical for the biomedical application. In principle, the multi­scale modeling
of genotype­phenotype associations will facilitate opening the black box of machine learning [102].
For example, the embedding from the transcriptomics profile, directly or indirectly, can be used to
elucidate biological pathways responsible for the synergy of drug combinations [103]. In addition
to the above fundamental challenge, the predictive modeling of genotype­phenotype associations
faces several technical difficulties that hinder the application of existing machine learning methods.
Firstly, omics data are often in an extremely high dimension. Secondly, the coherently labeled data
are scarce compared with unlabeled data. Finally, it is not a trivial task to integrate heterogeneous
omics data from different resources and modalities.
We develop a novel neural network­based framework: Cross­LEvel Information Transmis­
sion (CLEIT) network to address the aforementioned challenges. Inspired by domain adaptation
techniques, CLEIT first learns to construct the low­dimensional latent representation that encodes
signals indicative of tasks at hand from a high­level domain. Then, CLEIT uses the embedding from
the high­level domain as ground­truth embedding to regularize the representation learning of the
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low­level domain in the form of a contrastive loss. In addition, we adopt a pre­training­fine­tuning
approach, where pre­training enables the usage of unlabeled heterogeneous omics data to improve
the generalizability of CLEIT, while fine­tuning is employed to enable more task­focused predictions
given a specific labeled dataset.
As a demonstration of CLEIT’s efficacy in a biological setting, we applied CLEIT to predict­
ing anti­cancer drug sensitivity from somatic mutations. Precision anti­cancer therapy tailed to indi­
vidual patients based on their genetic profile has gained tremendous interest in clinical [104]. Exist­
ing studies such as [105], [106] focused on inferring drug response based on most salient mutation
gene signatures. Although the drug response of several successful targeted therapies, e.g., kinase
inhibitors, can be predicted from a few driver mutations harbored in patients, the percentage of US
patients who can benefit from the targeted therapy is only about 4.9% [107]. The choice of optimal
therapy for most cancer patients remains a significant challenge [108]. It is well known that cancer
acquires numerous mutations during its somatic evolution. Both driver and passenger mutations col­
lectively confer cancer phenotypes and are associated with drug responses [109]. Thus it is necessary
to use the entire mutation profile of cancer to predict anti­cancer drug sensitivity in most cases. The
machine learning models that can explicitly model hierarchical biological processes will undoubtedly
facilitate the development of personalized medicine. Our extensive experiments show that CLEIT
significantly outperforms other state­of­the­art methods in this regard.
Related Works
CLEIT aims to develop a framework that constructs an indicative knowledge­abundant low­
dimensional latent space from a high dimensional feature space of particular domains, which lacks
salient discriminative information of tasks of interest. For example, although somatic mutation data
undoubtedly posses biology­rich information, its sparsity and binary characteristics often make it
extremely challenging to be utilized to build effective machine learning models for downstream pre­
dictive tasks. To combat such data limitation issues, we seek to transfer knowledge from other levels
of omics data to regularize the learning of mutation data training. If we treated different levels of
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multi­omics data as from different data domains, we could incorporate domain adaptation­insipred
strategies to encourage the knowledge transfer from one to another. In particular, we explored the
feature­based domain adaptation techniques as detailed in Chapter 2.
To be noted, the multi­modal integration of somatic mutation and gene expression data has
been utilized to improve predicting anti­cancer drug sensitivity, e.g., in [97] and [110]. These meth­
ods assume that both labeled mutation data and labeled gene expression data are available during
training and inference. Additionally, they integrate omics data horizontally. In contrast, CLEIT only
needs to use the mutation data as the input during the inference stage. During the training stage, the
mutation and gene expression data can come from different data resources and be unlabelled. Thus,
CLEIT is more practical than existing methods. Moreover, CLEIT explicitly models the hierarchical,
asymmetrical information transmission in a biological system, as shown in Figure 4.1.
Contributions
CLEIT aims to address an important problem of multi­scale modeling of genotype­phenotype
associations. Although CLEIT borrowed some ideas from the domain adaptive transfer learning,
there is a significant difference between CLEIT and those approaches. The goal of classic domain
adaptation is to use the label information from the source domain data to boost the performance of
supervised tasks in the target domain without abundant labels. The feature in the target domain usu­
ally has a similar discriminative power to that in the source domain. While in our case, we focus on
resolving the inherent discriminative power discrepancy between two hierarchical related domains.
The feature of the high­level domain has higher discriminative power than that of the low­level do­
main. Moreover, the entity types of source and target domains are usually the same in conventional
domain adaptation. In our case, they are of different types. Specifically, our goal for information
transmission is to solely push the latent representation of the low­level domain to approximate the
one of the high­level domain; that is, the feature representation learned from the high­level domain
is fixed and used as ground­truth feature representation of the low­level domain. In this setting, the
latent space where the cross­level information transmission happened is no longer a symmetrical
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consensus from different domains. The high­level and low­level domain is used as an input and an
output, respectively, to boost the discrimination power of the low­level domain. A mapping function
is learned between them.
The major contributions of this research are summarized as follows.
­ We propose a novel neural network framework that can explicitly model asymmetrical cross­
level information transmissions in a complex system to boost the discriminative power of the low­
level domain. The multi­level hierarchical structure is the fundamental characteristic of the biologi­
cal and ecological system. The proposed architecture is general and can be applied to model various
machine learning tasks in a multi­level system.
­ The proposed neural network framework provides a new approach to integrating multiple
omics data vertically to represent the multi­level organization of a biological system.
­ We design a pre­training­fine­tuning strategy to fully utilize both labeled and unlabeled omics
data that are naturally noisy, high­dimensional, heterogeneous, and sparse.
­ In terms of biomedical application, the CLEIT model significantly improves personalized
anti­cancer drug sensitivity prediction using only somatic mutation data. To the best of our knowl­
edge, CLEIT is the first deep learning­based framework designed to perform drug sensitivity pre­
diction tasks solely on whole­genome somatic mutation profiles, which achieves comparable perfor­
mance to the model trained from gene expression profiles. The oncology panel of somatic mutations
has been routinely performed in cancer treatment. The application of CLEIT may improve the effec­
tiveness of cancer treatment and achieve personalized medicine.
Method
Problem formulation
We denote a data domain D as D = {X , P (X)}, where X stands for the feature space and
samples within domain D, X = {x1, . . . , xn} ∈ X . P (X) is the affiliated marginal distribution.
In this work, we consider two domains DH = {Xh, Ph(Xh)} and DL = {Xl, Pl(Xl)}, namely
the high­level domain and low­level domain, where Xh ̸= Xl, Ph(Xh) ̸= Pl(Xl). In addition, one
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Figure 4.2: CLEIT Framework. The training of CLEIT involves five steps. First, the encoder of DH is
learned from an autoencoder and fine­tuned by a supervised multi­task MLP in steps 1 and 2. Then, the
embedding of DL is encoded from an autoencoder in step 3, and the difference between it and that of DH is
minimized via an MLP transmitter in step 4 as measured by contrastive loss. In step 5, the supervised model of
DL is fine­tuned by the model that appends the pre­trained multi­task MLP of DH in step 2 and the
regularized encoder of DL in step 3.
common task τ of interest is to predict phenotype or other outcomes. This task can be done individu­
ally from both domains but with different performance, where DH can achieve superior performance
to DL independent on machine learning models applied to them. Here, the performance difference
is due to the nature of each domain, instead of the volume of labeled samples as in a classical do­
main adaptation setting. However, although feature space Xh and Xl are not the same, the entities
cross the feature spaces are hierarchically related, such as the multi­level hierarchical organization of
omics data of a biological system. Based on this realization, this work aims to utilize the knowledge
learned from DH to boost the predictive power of DL.
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CLEIT framework
To use the knowledge learned from DH to boost the performance of DL, we propose a Cross­
LEvel­Information Transmission (CLEIT) framework. The strategy of CLEIT is to encode the data
from both domains into certain ”higher­level” features. The embedded ”high­level” feature has
the direct implication of the task of interests and achieves the cross­level information transmission
through transferring knowledge via learned representations cross domains.
Figure 4.2 shows the overall framework of CLEIT. The training of CLEIT involves five steps:
1) learning an embedding of DH from unlabeled data using standard autoencoder (AE) [111], 2) fine­
tuning the pre­trained embedding of DH from step 1 using a multi­layer perceptron (MLP) in the
setting of multi­task supervised learning, 3) and 4) learning an embedding of DL from unlabeled
data using AE along with the embedding regularization between DL samples and corresponding DH
samples in the form of an MLP­based transmitter training 5) supervised learning of the final predic­
tive model of DL using an architecture that appends the pre­trained multi­task MLP (as a warm start)
from step 2 as well as the pre­trained AE encoder and the transmitter of DL from steps 3 and 4. We








where NH· stands for the number of samples in corresponding data sets. Furthermore, zH· is used to
symbolize the latent vectors (embeddings) learned in different phases throughout the training. Sam­
ples from the DL are similarly denoted.
High­level domain DH encoder training and fine­tuning
For the pre­training of DH , we first construct an autoencoder [111] to ”warm” the encoder
with standard input reconstruction task over the unlabeled DH samples. Then, in the fine­tuning step,
we append a task­specific neural network module to re­tune the pre­trained encoder to learn high­
level task­specific representations. In our setting, we focus on predicting the drug sensitivity of a
particular sample against a list of pre­selected drugs, where the anti­cancer sensitivity of each spe­
cific drug can be seen as an individual task. To acknowledge that different drugs may have different
medicinal mechanisms, we designed the predictor module as follows. We first append one shared
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layer after the pre­trained encoder module and then append non­sharing additional fully connected
layers to make a complete predictor for each task (drug). In this manner, the shared layer(s) of the
predictor and the encoder module are assumed to capture the salient biological features that are gen­
erally useful for drug sensitivity prediction. And, each non­shared layer will translate such features
in accords to each drug’s specific mechanism. The drug sensitivity is metricized by a continuous­
valued metric (area under the dose­response curve), making the task a regression problem. Last but
not least, we design a masked mean squared error with ranking penalty term (shown in equation
(4.1)) as our fine­tuning process loss function. On the one hand, this loss allows the missing values
in the multi­dimension label space. On the other hand, the ranking penalty term pushes the loss to
spare some focus on the correct relative ordering of a particular drug’s sensitivity against the list of
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where α is the corresponding weighting item for the ranking penalty term in equation (4.1) and
NDrug is the number of drugs in consideration. y ∈ Rk with potential missing values is the ground­
truth drug sensitivity scores between a drug and k total samples (or the number of samples within
a batch), correspondingly, and ŷ ∈ Rk is the predicted drug sensitivity scores. I[ykj ̸=NA] is a binary
indicator vector of length k, that stands for the presence/absence of ground­truth score for this drug
against all the labeled samples and k∗ accordingly is the total number of samples with ground­truth
sensitivity score for this drug.
Moreover, in the fine­tuning phase, we started with updating only appended predictor module
and then employed gradual unfreezing and layer­wise decayed learning rates to update the encoder.
After the training of DH , the encoder is frozen to generate ”ground­truth” latent representation of
DH , while the appended predictor module can be preserved to serve as initialization checkpoint for
predictor module in DL to facilitate the corresponding training process.
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Low­level domain DL encoder and transmitter training
The pre­training procedure of DL is mostly the same as the one used for the encoder pre­
training of DH . However, different from DH , where the encoder training in DH is an intermediate
step to improve the generalizability by leveraging more available unlabeled data. The pre­training
process of DL in CLEIT is also responsible for incorporating knowledge from DL to enhance the
quality of encoder representation learning.
As shown in Figure 4.2, for the encoder pre­training of DL we also use an autoencoder recon­
struction task with unlabeled data. The key innovation lies in the information transmitter module
between the hidden representations of two domains. As introduced earlier, we considered the latent
representation generated by DH encoder as the ”ground­truth” representation to which DL encoder
aims to approximate. We utilize the additional transmitter module to explicitly bridge the asymmet­
rical encoding process between DH and DL. Specifically, the transmitter is responsible for minimiz­
ing the discrepancy between the hidden representations of two domains. Such minimization task is
formulated as a cross­level information transmission loss (Lclr) between representations of the same
sample from different domains. Lclr is used as additional regularization to guide the training of en­
coder of DL. We then train the encoder in a multi­task setting, where the training loss is defined as
a weighted combination of AE loss (LAE) and cross­level information regularization loss (Lclr) as
shown below,
Lcleit = λLclr(zL, zH) + (1 − λ)LAE(xLu , x̂Lu , zLu) (4.2)
where λ is a user­specified hyper­parameter to balance the loss terms. When λ = 0, the training does
not use any information transmitted across domains. F stands for additional transmitter module. zLu
captures the domain specific information with the autoencoder affiliated reconstruction task, while
the transmitted representation zL = F (zLu), transformed directly from zLu , is to mimic the ”ground­
truth” embedding from DH , which will be further utilized to perform downstream tasks. In the ab­
sence of transmitter, zLu will be further burdened with ground­truth emebdding matching, which may
cause challenges in the actual training process. In this work, a two layer fully connected MLP is used
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as the transmitter.
We used contrastive loss in the transmitter to measure the difference between embeddings. The
contrastive loss is adopted from the self­supervised learning framework SimCLR [112]. We consider





























z(k)L∥∥∥z(i)H ∥∥∥ ∥∥∥z(k)L ∥∥∥ (4.5)
I[k ̸=i] is the binary indicator vector of condition (k ̸= i) and the cross­level information regulariza­
tion loss is computed as the average contrastive loss between all positive pairs within one batch.
After incorporating the cross­level information regularization loss into the encoder pre­
training, we can leverage all the samples that have features in both domains regardless of the label’s
availability. We denote samples used in the pre­training phase of DL as {(x(i)L , x
(i)
H )}Ni=1, N is the
total number of samples that have features in both domains. In the supervised fine­tuning phase of
DL, the inherited predictor modules from the training of DH are appended after DL encoder and
transmitter to accelerate the initial training on these modules. Like DH encoder fine­tuning, we also
employed similar gradual unfreezing, as well as the layer­wise decayed learning rate, in the training
of encoder and transmitter modules. A detailed DL training procedure can be found in (Procedure
1).
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Procedure 1 DL training procedure






Require: nu, number of pre­training epochs
nf , number of epochs to keep encoder frozen
nuf , number of epochs to unfreeze one more layer
α, initial learning rate in fine­tuning
δ, learning rate decay coefficient;
θ, all trainable parameters, begin with only predictor modules
1: for epoch = 1 to nu do
2: Update DL autoencoder and transmitter with Lcleit
3: end for
4: for epoch = 1 to nf do
5: Update θ with Lsi−mse
6: end for
7: epoch = 0
8: repeat
9: if epoch %nuf == 0 then
10: Expand θ with highest frozen layer of encoding module (pre­trained encoder + transmitter)
11: α = α ∗ δ
12: end if
13: Update θ with Lsi−mse
14: until Stop Condition
In practice, the stopping condition to terminate the fine­tuning of DL, can be in the form of
either pre­specified maximum number of epochs or early stopping with a validation dataset.




We evaluate the performance of CLEIT on a real­world problem: predicting anti­cancer drug
sensitivity given the mutation profile of cell lines. The mutation profile (oncology panel) has been
implemented in the clinic but has weaker discriminative power for drug sensitivity prediction than
the gene expression profile that is not a clinical standard yet. We collected and integrated data from
several diverse resources: cancer cell line data from CCLE [113], pan­cancer data from Xena [114],
drug sensitivity data from GDSC [93], and gene­gene interactions from STRING [115]. CCLE in­
cludes 1305 and 1697 cancer cell line samples with the gene expression profile and the somatic mu­
tation profile, respectively. The pan­cancer data sets include 9808 and 9093 tumor samples with
the gene expression profile and the somatic mutation profile, respectively. Specifically, we only
keep the mutation profiles of samples with matched gene expression profiles in our unlabeled mu­
tation data set. All gene expression data are metricized by the standard transcripts per million base
for each gene, with additional log transformation. For the somatic mutation data, we kept only non­
silent genes then propagated the mutated genes in each sample on a STRING gene­gene interaction
network using pyNBS [116]. We selected the top 1000 varied genes measured by the percentage of
unique values in gene expression samples for cancer cell lines and tumor tissue samples separately.
Then we combined the two sets of top 1000 varied genes as the input features. The union has 1424
unique genes in total. Additionally, we only kept the genes present in the mutation profiles as our
final raw feature sets, although CLEIT does not require it. We did so for a fair comparison to other
domain adaptation methods since all other methods in comparison consist of a shared encoder com­
ponent that requires the same number of input features across domains. The final feature set consists
of 1407 genes. Furthermore, we matched the omics data of CCLE cell lines against the GDSC drug
sensitivity score measured by the Area Under Drug Response Curve (AUC), which is presented as
the fraction of the total area under the drug response curve between the highest and lowest screen­
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ing concentration in GDSC [93]. In total, we assembled 680 CCLE cell lines with both mutation and
gene expression, which are associated with 93 anti­cancer drugs after removing drugs that have more
than 10% missing drug sensitivity measurements within these cell line samples. These 680 cell lines
and 59,203 drug sensitivity data were used as training data in the fine­tuning stage. 278 cell lines
have only mutation information. These data were used as hold­out testing data in our study. Addi­
tionally, 11,113 and 9,743 samples do not have measured drug sensitivities. These unlabeled data
were used in the pre­training stage. The gene expression profile is considered as DH , while the muta­
tion is DL. A summary of the pre­processed data are shown in Table 4.1.







(#cell lines) 11113 680 NA
Somatic Mutation
(#cell lines) 9743 680 278
Drug Sensitivity
(#cell line­drug pairs) NA 59203 23475
Training and testing procedure
To demonstrate CLEIT’s stable performance in the given anti­cancer drug sensitivity predic­
tion task, we repeated the model training five times. First, we split the labeled fine­tuning dataset
that has both gene expression and mutation profile into 5 folds. Then, in each repetition, we used
four out of five folds as the labeled training set, the remaining one fold left as the validation set.
Moreover, the detailed training procedure of CLEIT is listed as follows. In the DH pre­training, we
trained CLEIT for N epochs. With parameter grid search, N is selected based on the target task per­
formance. While for the fine­tuning of DH , we employed early stopping with validation labeled fold
(only gene expression) as mentioned earlier in this section. For the pre­training of DL, similar to pre­
training of DH , we specified the number of epochs based on the task­specific performance. In the
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fine­tuning of DL, we employed early stopping with the same validation fold (only mutation) in the
fine­tuning of DH . The final trained model is used to make predictions on a labeled mutation­only
test set. All other baseline models followed the same training and testing procedure.
Performance Evaluation
We evaluated CLEIT’s performance by predicting drug sensitivity on a hold­out labeled
mutation­only test data. We measured the regression performance using Pearson correlation,
Spearman correlation, RMSE (root mean squared error). Note that there is a maximum of 93 drug
sensitivity scores associated with each cell line sample. The results are shown with the average
performance per cell line sample (sample­wise) and per drug (drug­wise). Besides, because of the
incompleteness of the ground truth matrix, the prediction entries without a ground truth sensitivity
score are filtered out in the calculation of each evaluation metric.
Baseline models
We compared CLEIT with the following base­line models: MLP without and with the AE
pre­training for DL as well as several of the most popular domain adaptation algorithms that are
used to transfer the knowledge learned from DH to DL. They include Deep Domain Confusion
(DDC) network [76], Correlation Alignment (CORAL) [79], Domain Adversarial Neural Network
(DANN)[83], Adversarial Domain Adaptation Network (ADDA) [84] and Domain Separation Net­
work (DSN) [89]. Specifically, DDC, CORAL, DANN, and ADDA only made use of the labeled
data (same dataset and procedures adopted in the fine­tuning phases of CLEIT), while DSN utilized
both the unlabeled and labeled data (same dataset and procedures adopted in the pre­training and
fine­tuning phases of CLEIT). For domain adversarial loss in DSN, we employed the MMD variant
for the stability of training.
To evaluate the contribution of different components in CLEIT, we performed ablation studies
by 1) removing the transmitter, 2) change the cross­level transmission loss function to Maximum
Mean Discrepancy (MMD) loss [74] and Earth Mover distance approximated using Wasserstein­
GAN (WGAN) [117]. The latent dimension for hidden representation for all models is specified as
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128, and all autoencoder frameworks share the same [512, 256, 128, 256, 512] architecture. Besides,
all pre­trained encoders will be appended with a predictor module of the same architecture ([128]
shared layer + [64,32] individual drug MLP) for the fine­tuning process.
Results and Discussion
Gene expression feature has stronger predictive power than somatic mutation­based feature
Figure 4.3 shows that the performance comparison between the regression models trained us­
ing only gene expression features and those trained by only somatic mutation features to predict anti­
cancer drug sensitivity. Two neural network models were compared. One was to use an unlabeled
pre­trained encoder (denoted as MLP+AE), and the other was to use a randomly initialized encoder
(denoted as MLP). All models compared here were trained and tested using the labeled fine­tuning
dataset listed in Table 4.1 based on the five­fold cross­validation because we need the exact same
testing cases with both gene expression and somatic mutation data. Consistent with extensive per­
formance evaluations from blind tests in a DREAM challenge [97], and other studies [100], the gene
expression feature has more substantial predictive power than the mutation­based feature. As shown
in Figure 4.3 (a), the model trained with only labeled gene expression data has a 6.45% performance
gain over the model trained with corresponding labeled somatic mutation data when evaluated us­
ing a sample­wise average. With the additional utilization of unlabeled pre­training, models trained
with only gene expression data and only the mutation data both showed slightly better performance,
while their performance gap is around 6.8%. In terms of drug­wise average, as shown in Figure 4.3
(b), the performance gap between models built on mutation­only and expression only data is even
more apparent. These results confirmed that the gene expression is more predictive than the somatic
mutation for predicting the anti­cancer drug sensitivity.
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(a) Sample­Wise Average (b) Drug­Wise Average
Figure 4.3: Performance comparison of the model trained using only gene expression features with that using
only somatic mutation features, and tested with the same data set.
CLEIT can transfer the knowledge learned from gene expression features to the model with
mutation features
To demonstrate that CLEIT can transfer the knowledge learned from the gene expression fea­
ture to the model that uses the mutation­only data, we compared the drug­wise Pearson correlation
distribution of CLEIT with those of the MLP+AE models trained with only gene expression or mu­
tation data. Figure 4.4 shows the histogram of Pearson correlations of 93 drugs for three models.
CLEIT with the mutation data shifts the performance distribution close to the model trained using
the gene expression data, which has significantly better performance than the MLP+AE model with
the mutation data. It is aligned with our primary goal in this work. Note that the histograms in Fig­
ure 4.4 were from the validation data. Next, we evaluate the performance of CLEIT in a hold­out
mutation­only test data.
CLEIT significantly outperforms state­of­the­art models to predict anti­cancer drug sensitivity
using mutation­only data
Given that gene expression data have stronger predictive power than somatic mutation data, we
evaluate if CLEIT can use the gene expression to boost the performance for predicting anti­cancer
drug sensitivity when only the somatic mutation data are available as the input. The results for both
drug­wise and sample­wise evaluation are shown in Table 4.2 and Table 4.3. As seen in those tables,
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Figure 4.4: Drug­wise pearson correlation on validation dataset.
Table 4.2: Evaluation Results on Test Data (Drug­wise).
Method Pearson Spearman RMSE
MLP (mutation­only) 0.0591±0.0069 0.0532±0.0066 0.0233±0.0018
MLP+AE (mutation­only) 0.0681±0.0085 0.0629±0.0108 0.0151±0.0001
DDC[76] 0.0633±0.0087 0.0621±0.0087 0.0150±0.0006
CORAL[79] 0.0580±0.0105 0.0542±0.0080 0.0164±0.0005
DANN[83] 0.0571±0.0061 0.0516±0.0038 0.0173±0.0010
ADDA[84] 0.0681±0.0111 0.0685±0.0142 0.0197±0.0010
DSN[89] 0.1003±0.0186 0.0915±0.0252 0.0147±0.0007
CLEIT (w/o transmitter) 0.2587±0.0126 0.2254±0.0348 0.0124±0.0006
CLEIT (MMD) 0.1758±0.0086 0.1421±0.0200 0.0148±0.0009
CLEIT (ADV) 0.0795±0.0083 0.0821±0.0106 0.0150±0.0009
CLEIT 0.2770±0.0086 0.2482±0.0243 0.0121±0.0006
models that consist of unlabeled pre­training processes generally outperform the models trained with
only labeled data, indicating the importance of leveraging unlabeled data. The models trained with
domain adaptation methods with unlabeled pre­training (DSN or CLEITs) or only labeled training
Chapter 4: CLEIT 53
Table 4.3: Evaluation Results on Test Data (Sample­wise).
Method Pearson Spearman RMSE
MLP (mutation­only) 0.7390±0.0017 0.6957±0.0022 0.0235±0.0017
MLP+AE (mutation­only) 0.7450±0.0003 0.6984±0.0004 0.0150±0.0001
DDC[76] 0.7449±0.0017 0.7010±0.0010 0.0151±0.0004
CORAL[79] 0.7439±0.0013 0.7002±0.0010 0.0165±0.0004
DANN[83] 0.7428±0.0017 0.6995±0.0019 0.0174±0.0008
ADDA[84] 0.7315±0.0053 0.6891±0.0010 0.0199±0.0008
DSN[89] 0.7470±0.0002 0.7024±0.0004 0.0148±0.0004
CLEIT (w/o transmitter) 0.7569±0.0081 0.7172±0.0070 0.0125±0.0005
CLEIT (MMD) 0.7443±0.0018 0.7003±0.0009 0.0147±0.0009
CLEIT (ADV) 0.7465±0.0005 0.7022±0.0008 0.0152±0.0009
CLEIT 0.7640±0.0094 0.7233±0.0063 0.0122±0.0005
outperform their non­adaptation counterparts. It implies that DL will benefit from the knowledge
transfer from DH . Furthermore, CLEIT models significantly outperform all other models in consid­
eration (t­test p­value < 0.05). The best­performed model is the CLEIT that uses contrastive loss.
Compared with the best performed state­of­the­art model (DSN), the accuracy of CLEIT, when mea­
sured by Pearson correlation, improves 277% and 2.2% for the drug­wise and the sample­wise test,
respectively. Similar results can be seen in terms of Spearman correlation and RMSE. The perfor­
mance gain of CLEIT over MLP and MLP+AE is 3.4% and 2.5%, respectively, in the sample­wise
setting, yet in the drug­wise setting, the improved gap is enlarged to 469% and 407%. The much im­
proved drug­wise performance achieved by CLEIT indicated a much higher quality drug­sensitivity
prediction with the mutation­only data.
CLEIT models that incorporate MLP­transmission function show significantly better perfor­
mance than those without, suggesting that the transmission function plays a role in CLEIT. Choice of
the loss function in the information transmission is also important. It is clear that contrastive loss per­
forms better than MMD and WGAN. It is noted that MMD is used in DSN. When CLEIT uses MMD
as the loss function to measure the domain discrepancy, the major difference between CLEIT and
MMD is that CLEIT treats the information transmission between two domains asymmetrical, while
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DSN considers domain adaptation symmetrical. The results in Table 4.2 and Table 4.3 show that
CLEIT­MMD outperforms DSN in drug­wise setting and perform similarly in sample­wise settings.
It indicates that the explicit modeling of the hierarchical organization of DL and DH is important.
CLEIT outperforms state­of­the­arts for predicting top­ranked cell­line specific anti­cancer
therapies
Furthermore, CLEIT can predict the best therapy for a new patient using only mutation data
for personalized medicine. We compared the performance of different methods with the precision of
top­k (k = 1, 3, 5, 10) predictions ranked by the AUC scores, which is defined as the ratio of drugs
with top­k smallest predicted scores per cell line among the drugs with top­k ground­truth scores.
Mutation­only test results can be found in Figure 4.5. Clearly, the CLEIT model also outperforms
other models in this scenario. Compared with the second­best performed model DSN, CLEIT im­
proves the performance by approximately 11% when k = 3.
Conclusion
This paper proposed a novel machine learning framework CLEIT for the predictive modeling
of genotype­phenotype associations by explicitly modeling the asymmetric cross­level information
transmission in the biological system. Using the anti­cancer drug sensitivity prediction with only
mutation data as a benchmark, CLEIT clearly outperforms existing methods and demonstrates its po­
tential in personalized medicine. Although we only study the knowledge transfer between DNA level
and RNA level in this paper, the same strategy can be applied to other levels in the biological system,
for example, imputing proteomics data using transcriptomics data. Nevertheless, the performance of
CLEIT could be further improved by incorporating domain knowledge. For example, an autoencoder
module that can model gene­gene interactions and biological pathways will be greatly helpful. Under
the framework of CLEIT, it is not difficult to integrate other omics data such as epigenomics and pro­
teomics. They may further improve the performance of CLEIT. Another challenge in personalized
medicine is to transfer knowledge from cell line data to patient tissue data [118]. It will be interesting
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Figure 4.5: Top k precision on mutation­only test dataset.
to develop new neural network architectures in the framework of CLEIT to address this problem.
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Chapter 5
COherent Cell line­Tissue DEconfounding Autoencoder (CODE­AE)
Introduction
Transcriptomics is a powerful technique to characterize cellular activity under various condi­
tions, allowing researchers to uncover the underlying associations among genes, biological pathways,
diseases, and environmental factors. Hence, this data source has been widely explored by studies
ranging from regulatory gene identification [11, 12] to disease biomarker discovery [13]. In partic­
ular, it has been utilized to construct predictive machine learning models for drug response, such as
in [15, 16]. However, the success of such predictive models largely relies on the availability of suf­
ficient amounts of data with coherent and comprehensive annotations. In clinical, we are often short
of a large number of patient samples with drug treatment and response history. For this reason, most
drug response predictive studies to date have mainly utilized transcriptomic profiles from panels of
in­vitro cancer cell lines as input features. Although such an approach is promising, the utility of
drug response models built with in­vitro data is often limited when applied to real patients due to the
genetic and environmental differences between in­vitro cell lines and patient­derived tissue samples
and confounding factors that may mask intrinsic biological signals.
To address the above challenges, we propose a Coherent Cell line­Tissue Deconfounding Au­
toencoder (CODE­AE) that can extract both common biological signals shared by incoherent sam­
ples and private representations unique to them, transfer knowledge learned from cell line data to
tissue data, and separate confounding factors from them. CODE­AE will allow us to generalize ex­
isting cell line omics data for robust predictive modeling of drug response to new patients, a critical
component for patient­specific drug screening and precision medicine. Specifically, in CODE­AE,
we devise a self­supervised training scheme to construct an encoding module that can be easily tuned
to adapt to the different downstream tasks. For the self­supervised training of encoder, we leverage
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both unlabeled cell line and tissue samples.
As a demonstration of the potential of CODE­AE in precision medicine, we apply CODE­AE
to predicting chemotherapy resistance for patients, which is a significant obstacle to effective can­
cer therapy. Lack of effective personalized chemotherapy tailored to individual patients often leads
to unnecessary suffering and reduces the chances of patient’s overall survival. Our extensive stud­
ies show that CODE­AE significantly outperforms state­of­the­art methods in terms of both accu­
racy and robustness. Thus CODE­AE provides a useful framework to take advantage of rich in vitro
omics data for developing generalized patient predictive models.
Related Works
Our goal is to learn an encoding function that maps a gene expression profile to a low­
dimensional vector (embedding) dominated by intrinsic biological signals from both in­vitro cell
lines and in­vivo tissue samples. For such representation learning problems, a well­established tech­
nique is an autoencoder (detailed in Chapter 2) and its variants, such as DAE[119] and VAE[120],
due to their low reliance on labeled data availability. In addition, CODE­AE also considers this
in­vitro and in­vivo sample differences close to the classifical domain adaptation task settings, we
also explored the feature­based domain adaptation techniques detailed in Chapter 2. Moreover, a
recent publication Adversarial Deconfounding Autoencoder [121], which incorporates autoencoder
and alternative adversarial training for similar goal as CODE­AE is also included in our benchmark
experiments.
Methods
Our Approach: COherent DE­confounding AutoEncoder (CODE­AE)
We proposed the CODE­AE to generate biologically informative gene expression embeddings
applicable to transfer between in­vitro and patient samples. CODE­AE employed the standard auto­
encoder as the backbone to leverage the unlabeled gene expression data sets. Inspired by the work on
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factorized latent space [122] and domain separation network [89], we encoded the samples (from cell
lines or tumor tissues) into two non­redundant embeddings, namely private embeddings and shared
embeddings. The first one is designed to capture the cell line or tissue­specific information. The lat­
ter contains the deconfounded biological meaningful information used to transfer knowledge across
cell lines and tissues.
CODE­AE Base
Figure 5.1: COherent Deconfounding AutoEncoder (CODE­AE) framework. a) CODE­AE Base architecture:
A layer­tying shared encoder Es learns to map both cell line and tissue samples to deconfounded biological
meaningful embeddings. Private encoders E·p learn to represent cell line/tissue specific information as private
embeddings. A shared decoder D reconstructs the input samples through the concatenation of private and
shared embeddings and the reconstruction quality is measured with Lrecon. The private and shared
embeddings are pushed apart through soft subspace orthogonality loss Ldiff b) Appended module of
CODE­AE­MMD: the concatenation of private and shared embeddings are kept similar with LMMD c)
Appended module of CODE­AE­ADV: the concatenation of private and shared embeddings are kept similar
with Ladv, where Ladv is in the form of min­max optimization between critic network F and other
components.
As shown in Figure 5.1, the CODE­AE takes expression vectors from in­vitro cell lines and pa­
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data set of Nt patient tumor tissue samples and Nc in­vitro cancer cell line samples, respectively.
Each sample x will be encoded into two separate embeddings through its corresponding cell line or
tissue private encoder E·p and also the weight­sharing encoder Es. The concatenation of these two
embeddings of each sample is expected to be able to reconstruct the original gene expression vector
x through a shared decoder D, and the reconstruction is done as,
x̂(i)· = D(Es(x(i)· )
⊕
E·p(x(i)· )) (5.1)
where x(i)· represents the input gene expression profile, x̂
(i)
· is the corresponding reconstructed input
sample through the autoencoder component.
⊕
stands for the vector concatenation operation. We
measure the quality of autoencoder reconstruction through the mean squared error between the origi­












∥∥∥∥x(i)t − x̂(i)t ∥∥∥∥2
2
(5.2)
In our formulation, we factorized each sample’s latent space into two different subspaces to capture
both domain specific and common information separately. To minimize the redundancy between the
factorized latent spaces, we included an additional penalty term, Ldiff in the form of orthogonality
constraint. The difference loss Ldiff , is applied to both cell line and tissue samples and encourages
the shared and private encoder to encode different aspects of the inputs. We define the loss via soft
subspace orthogonality constraint as below,
Ldiff =
∥∥∥ZTcsZcp∥∥∥2F + ∥∥∥ZTtsZtp∥∥∥2F (5.3)
where Z·s are the embedding matrices whose rows are the shared embedding for cell line or tissue
samples, while Z·p are the embedding matrices whose rows are the private embedding for cell line or
tissue samples. It is obvious that Ldiff tends to push the embeddings to meaningless all­zero­valued
vectors. To avoid such scenario, we append an additional instance normalization layer after the out­
put layer of each encoder to avoid embeddings with minimal norm. Lastly, the loss for CODE­AE­
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BASE is defined with the weighted combination between Lrecon and Ldiff as below,
Lcode−ae−base = Lrecon + αLdiff (5.4)
where α is the embedding difference loss coefficient.
CODE­AE Variants
With CODE­AE­BASE, we could split cell line or tissue sample’s inherent information into
the private and shared streams. However, in our baseline experiments, we often found that it was
sub­optimal or demonstrated varied performance. Thus, in this section, we proposed two variants
that showed better and generally more stable performance. Under the CODE­AE framework, for
each input sample, CODE­AE factorized it into two embeddings. The concatenation of these two em­
beddings is considered as the new representation of the original input. Given that all samples in our
consideration are gene expression profiles regardless of cell line or patient, we assumed that the new
representation of original input in the factorized latent space close to each in terms of distributional
differences.
CODE­AE­MMD. The first variant, named CODE­AE­MMD, utilized the well known max­
imum mean discrepancy [74] as the distance measurement between the latent representation of cell
line and tissue samples. Maximum Mean Discrepancy (MMD) loss [74] is a kernel­based distance
function between samples from two distributions. In particular, we used an approximate version of





















where Zc,Zt are embedding matrices for cell line and tissue samples respectively, whose rows are
the concatenations of each sample’s private and shared embedding. z(i)· , z(j)· are the i­th or j­th sam­
ples’ corresponding embedding vectors. In practice, N will be the batch size. Accordingly, the loss
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of CODE­AE­MMD is given as below,
Lcode−ae−mmd = Lcode−ae−base + βLMMD (5.6)
where β is the MMD loss coefficient.
CODE­AE­ADV The second variant, CODE­AE­ADV, employed adversarial training to push
the representations of cell line and tissue samples to be similar to each other. Specifically, we ap­
pended a critic network F that scores representations with the objective that consistently gives higher
scores for representations of cancer cell line samples. The encoders for tissue samples are given an
additional objective to generate the embedding that could fool the critic network to produce high
scores. In this manner, critic network and tissue sample encoders will play a min­max game in the
form of an alternative training schedule, which is adopted by Wasserstein generative adversarial net­
works [87]. To avoid unstable training commonly existing in alternative training schedules, instead
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where z· = z·s
⊕
z·p stands for new representation of input and z̃ = ϵzc + (1 − ϵ)zt and ϵ ∼ U(0, 1).
A detailed CODE­AE­ADV learning procedure can be found in (Procedure 2).
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Procedure 2 CODE­AE­ADV training





Require: N , the batch size
λ, generator loss coefficient
nw, number of warm­up epochs
nt, number of training epochs
ncritic, number of steps per encoders update
1: for epoch = 1 to nw do
2: for t = 1 to min(Nc,Nt)N do
3: sample {xc} of size N from {x(i)c }Nci=1 (w/o. rep)
4: sample {xt} of size N from {x(i)t }
Nt
i=1 (w/o. rep)
5: Update Etp , Ecp , Es, D with Lcode−ae−base
6: end for
7: end for
8: for epoch = 1 to nt do
9: for t = 1 to min(Nc,Nt)N do
10: sample {xc} of size N from {x(i)c }Nci=1 (w/o. rep)
11: sample {xt} of size N from {x(i)t }
Nt
i=1 (w/o. rep)
12: Update F with Lcritic
13: if t %ncritic == 0 then




After the encoder training with unlabeled data as mentioned above, the shared encoder Es
could be used to directly generate the deconfounded biological meaningful embedding vectors or
append a neural network module for specific downstream tasks. In the latter case, strategies such
as gradual unfreezing and decayed learning rate schedule could be adopted to improve task­specific
performance further, as shown in our following experiments.
Experiments Setup
Baseline models
We compared CODE­AE with the following base­line models: standard autoencoder (AE)
[111], denoising autoencoder (DAE) [119], and variational autoencoder (VAE) [120] as well as rep­
resentative domain adaptation methods including deep coral (CORAL) [80] and domain separation
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network (DSN) [89] of both MMD (DSN­MMD) and adversarial (DSN­ADV) training variants. Fur­
thermore, we included a more recent adversarial deconfounding autoencoder (ADAE) [121] given its
similar formation as DANN [83] and state­of­the­art performance in transcriptomics data sets. For
fair comparisons, all the encoder and decoder trained in the experiments share the same architecture.
Specifically, the hidden representation is of dimension 128. The encoders and decoder are 2­layer
neural network modules of dimension (512, 256) and (256, 512), respectively, with the rectified lin­
ear activation function. Appended modules such as critic network in CODE­AE­ADV, and classifier
network used for fine­tuning are 2­layer neural networks of dimension (64, 32) with rectified linear
activation, have one output node with linear activation in critic network and sigmoid activation in
classifier networks. Further, the loss weight terms in CODE­AE­MMD and CODE­AE­ADV are all
simply specified as 1.0.
For reference, we also included the classification performances of similarly fine­tuned ran­
domized initialized encoder (labeled as MLP). In addition, the elastic net classifier (labeled as EN)
trained on original cell line gene expression profiles also included in the comparison.
Data sets
We evaluated the performance of CODE­AE with a practical problem: predict chemotherapy
resistance given gene expression profiles of patients while training the predictive model only using
the gene expression of cancer cell lines. We collected the cancer cell line gene expression profiles
from the DepMap portal [113] and corresponding drug sensitivity data from GDSC [93, 94]. Addi­
tionally, we collected patients’ tumor tissue gene expression profiles from the Xena portal [114]. In
total, we gathered 1305 cancer cell lines and 9808 patient tumor tissue samples with corresponding
gene expression profiles, respectively. All gene expression data are metricized by the standard tran­
scripts per million base for each gene, with additional log transformation.
Clinical chemotherapy resistance can be defined as either a lack of reduction in the size of tu­
mor following chemotherapy or the occurrence of clinical relapse after an initial “positive response
to treatment” [105]. Hence, we extracted data sets to assess these two aspects. The patient clinical
drug response was acquired from a recent work [123], where patients’ clinical response records of
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two chemotherapy agents Gemcitabine and Fluorouracil from The Cancer Genome Atlas (TCGA)
[95] were extracted. The patients were split into two groups: responders who had a partial or com­
plete response and non­responders who had a progressive clinical disease or stable disease diagnosis.
Only patients on single­drug therapy through the entire duration of treatment were retained in the
study.
In addition to using clinical diagnosis to indicate patients’ drug responses towards a particular
drug, we extracted patients ”new tumor events days after treatment” from TCGA [95] as the stan­
dard to divide patient into responders and non­responders. The median number of days of new tumor
events was used as the threshold. Similar to the above data set from [123], we only included patients
on single­drug therapy through the entire treatment duration in this test data set. Due to the limited
size of patients’ samples, we only included patients who received Cisplatin and Temozolomide in
this test data set.
Training procedure
We selected the top 1000 varied genes measured by the percentage of unique values for cancer
cell lines and tumor tissue samples separately. Then we combined the two sets of top 1000 varied
genes as the input features. The union has 1424 unique genes in total. We first pre­train different
variants of the autoencoders as mentioned above using the same unlabeled samples from both cancer
cell lines and tumor tissues. Then we fine­tune the pre­trained encoders with appended classification
module over labeled cancer cell line samples and corresponding drug sensitivity data. Specifically,
we first selected all cell lines with corresponding drug sensitivity measured in the area under the drug
response curve (AUC). We further categorized these cancer cell lines’ sensitivity against this drug
into binary labels, namely resistant or responsive. In particular, for the drug sensitivity measured in
AUC, it was presented as the fraction of the total area under drug response curve between the highest
and lowest screening concentration in GDSC [93, 94]. We set the AUC threshold as the value that
produced the best classification performance of an elastic net classifier given different drugs. The
number of training cell line samples (responsive/resistant) and test tumor tissue samples for differ­
ent drugs sensitivity prediction tasks are summarized in Table 1. During the fine­tuning stage, the
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Table 5.1: Training/Test samples class distribution in CODE­AE
Training (cancer cell lines) Test (patient tumor tissues)
responsive resistant responsive resistant
Gemcitabine 301 376 37 55
Fluorouracil 23 644 34 24
Cisplatin 291 377 20 20
Temozolomide 19 660 25 24
cell line samples were split into ten stratified folds (according to cancer types). In one evaluation it­
eration, nine out of ten folds of the samples were used as the training set. The remaining one fold of
samples was used as the validation data set for early stopping of fine­tuning process.
Performance evaluation
We choose the area under the receiver operating curve (AUROC) as the measurement metric
due to their insensitivity to changes in the test data set’s class distribution [124]. The model perfor­
mance was measured in AUROC over the patient tissue expression data and corresponding drug re­
sponse records. The performance of different methods was compared by the average of AUROCs of
ten iterations. It is noted that only cell line data were used for the model training and hyperparameter
selections, and all patient data were purely used for the testing.
Results and Discussion
Chemotherapy resistance prediction
We evaluated clinical chemotherapy resistance in two aspects: either a lack of reduction in the
size of tumor following chemotherapy or the occurrence of clinical relapse after an initial “positive
response to treatment” [105] as described in Section 4.2. The results are shown in Figure 5.2 and
Figure 5.3, respectively. Based on these results, we have the following observations.
Observation 1. CODE­AE­ADV significantly outperforms the state­of­the­art methods.
On average, CODE­AE­ADV shows the highest value of AUROC for all four drugs tested. We
performed a two­sample t­test on the AUROC performance between CODE­AE­ADV and the best
non­CODE­AE method for each drug, as shown in Table 5.2. Among three of four drugs (Gemc­
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Figure 5.2: The left and right figures show the performance of different methods trained with the drug
sensitivity of cancer cell lines for predicting patients’ response to chemotherapy agents Gemcitabine and
Fluorouracil, respectively. Patients’ drug responses are measured with clinical diagnosis.
itabine, Cisplatin, and Temozolomide), CODE­AE­ADV significantly outperforms other methods.
For the drug Fluorouracil, the performance CODE­AE­ADV does not significantly improve the
second­best performer VAE, but is significantly better than other state­of­the­art methods CORAL
and ADAE. Moreover, CODE­AE­ADV is more robust than other methods, as demonstrated by rela­
tively smaller variants of the performance.
Observation 2. Private and shared embeddings of cell line and patient data contribute to
improving the performance of transfer learning. The major difference between CODE­AE­ADV
and ADAE is to disentangle shared and private embeddings between cell lines and patient tissues. It
is also true for the difference between DSN­ADV and ADAE. For all four drugs, CODE­AE­ADV
significantly outperforms ADAE. Among three of four drugs (Fluorouracil, Gemcitabine, and Cis­
platin), DSN­ADV also performs significantly better than ADAE. For the drug Temozolomide, the
performance difference between DSN­ADV and ADAE is not statistically significant (p­value =
0.194747).
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Figure 5.3: The left and right figures show the performance of different methods trained with the drug
sensitivity of cancer cell lines for for predicting patients’ response to chemotherapy agent Cisplatin and
Temozolomide, respectively. Patients’ drug responses are categorized based on number of days of new tumor
events after treatment.
Observation 3. Adversarial loss outperforms MMD loss. For all four drugs, CODE­AE­
ADV and DSN­ADV significantly outperform their variants CODE­AE­MMD and DSN­MMD,
respectively. The only difference between them is the loss function, adversarial loss or MMD loss.
Clearly, transfer learning between cell lines and patients may benefit from the adversarial training
that provides an effective way to sample the learning space.
Table 5.2: Average AUROC performance t­tests p­values
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Transferability of deconfounded representation of CODE­AE
To show that CODE­AE can generate transferable embedding through deconfounding uninter­
esting confounders while preserving true biological signals present in expression data even outside
the in­vivo and in­vitro setting. We selected the gene expression data sets used in ADAE [121] to
perform a similar evaluation process. Specifically, we chose the brain cancer expression data set
with gender information as confounding factors and brain cancer subtype classification as target
downstream tasks. We first performed encoder training with all unlabeled gene expression profiles
regardless of gender. For ADAE [121] and CODE­AE, we selected the binary gender variable as
the deconfounding target. After encoder training, we generated the latent embedding for all original
gene expression profiles using different encoders. Then, we built elastic net classifiers for cancer
subtype prediction using the latent embedding of samples of one gender to predict the other gender
samples. Following the evaluation procedure described in [121], the classification performance mea­
sured in the area under the precision­recall curve (AUPRC) as well as area under the receiver oper­
ating curve (AUROC) of ten­fold cross­validation was reported in Table 5.3. Besides, we performed
a two­sample t­test on the average performance between CODE­AE and the best non­CODE­AE
method in each setting, and its results are shown on the last row of Table 5.3. We observed the same
trends as those in the drug resistance prediction. Using the model built from female data to predict
male data, CODE­AE­ADV significantly outperforms ADAE, the second­best performer measured
by both AUROC and AUPRC. When applying the model trained from male data to predict female
data, the performance of CODE­AE­ADV is slightly worse than CORAL, but the difference is not
statistically significant. Both CODE­AE­ADV and CORAL significantly outperform the state­of­the­
art deconfounding method ADAE (p­value ≤ 0.05). Additionally, two other observations from the
chemotherapy resistance experiments hold. Disentangling common and private features of different
data modalities is essential for cell line to tissue transfer learning, and adversarial loss is more effec­
tive than MMD loss.
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Table 5.3: The best and the second best performances are highlighted and underlined, respectively
Female­>Male Male­>Female
AUROC AUPRC AUROC AUPRC
ADAE 0.9038±0.0081 0.9621±0.008 0.9264±0.0043 0.9755±0.0018
CORAL 0.8793±0.0208 0.9432±0.0042 0.9444±0.0057 0.9862±0.002
DSN­MMD 0.6772±0.0187 0.8715±0.026 0.6693±0.0584 0.9145±0.0189
DSN­ADV 0.7513±0.0341 0.9016±0.0086 0.8518±0.035 0.9608±0.0098
CODE­AE­BASE 0.603±0.0437 0.8613±0.0001 0.6276±0.0687 0.9112±0.0079
CODE­AE­MMD 0.9221±0.0186 0.9683±0.0056 0.939±0.0039 0.9826±0.0021
CODE­AE­ADV 0.9319±0.0018 0.9730±0.0007 0.9400±0.0074 0.9840±0.0033
P value of t­test 9.609e­07 0.0018956 0.157513 0.08213
Conclusion
In this paper, we introduce a new transfer learning framework CODE­AE to predict patient
drug response from a supervised neural network model trained from cell line data. Extensive bench­
mark studies demonstrate the advantage of CODE­AE over the state­of­the­art in terms of both accu­
racy and robustness. The performance gain of CODE­AE mainly comes from (1) the unsupervised
learning that combines unlabeled data from both cell lines and patient samples, (2) separation of
shared common features cross cell lines and patient samples with unique embedding for cell lines
or patients, and (3) adversarial training to optimize the similarity and difference between incoherent
data sets. CODE­AE could be further improved in several directions. In contrast with cell line data
from a pure population of cells, patient tissue data are mixtures of normal, abnormal, and infiltrated
immune cells. We can further improve the CODE­AE by the deconvolution of patient gene expres­
sion data. We only use transcriptomics profiles to build the predictive model in this study. We can in­
tegrate additional omics data such as somatic mutations and copy number variants in the framework
of cross­level information transmission [125]. Finally, we only apply CODE­AE to cancers. It will
be interesting to test the performance of CODE­AE in other diseases besides cancers, which even
do not have a large number of cell line data. In principle, CODE­AE can be applied to other transfer




How to better leverage unlabeled data is critical to robustly apply machine learning methods
to biomedical studies. In my dissertation, I focused on developing novel unsupervised representa­
tion learning algorithms to improve the predictive modeling performance using noisy, incoherent,
and sparse omics data. The fundamental assumption of the usefulness of unsupervised representa­
tion learning lies on the assumption that the factors (representation) that are helpful for the unsu­
pervised tasks can also be useful for related supervised tasks. And it can be achieved through a di­
rect mapping from low­level sensory data first, or via a pretraining procedure in the context of the
deep supervised network. Apparently, with the rapid advancement of deep learning in recent decade,
deep learning­based representation learning approaches attracted most of the attentions, compared
with conventional shallow model­based approaches, where only a “single layer”­transformation is
learned based on certain assumption over the new representation. Specifically, deep learning­based
approaches learn distributed representations, which encourages the reuse of features to represent
the concepts. Moreover, the deep neural networks have multiple hidden layers, where each layer
performs feature construction from the layers before it and the training process used allows layers
deeper in the network to contribute to the refinement of earlier layers. Therefore, essentially, a deep
architecture can be considered as formed by a hierarchical composition of multiple levels of repre­
sentations, which naturally leads to more progressively abstract features at higher layers of the archi­
tecture. This fact highlights the theoretical advantages of deep learning, i.e., learning a hierarchy of
features.
Moreover, a deep model is seen as a universal function approximator due to the exponential
representation power brought by the depth of the network as well as embedded nonlinear activation
in hidden layers. Such flexibility leads to multiple state­of­art models in a diverse array of tasks.
However, to properly fit the hidden layers requires a large set of training data to avoid overfitting,
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which impedes the adoptions of deep learning approaches in biomedical studies. One typical solu­
tion to overfitting, just like any other machine learning approaches, is to incorporate some external
information in the model to constrain its flexibility in the form of regularization techniques such as
the ones used in the variants of basic autoencoders. Besides, deep learning models are notoriously
difficult to train. On the one hand, it usually requires a very long computation time as well as pow­
erful hardware. On the other hand, there are often multiple hyperparameters used in one deep model,
such as number of layers, number of nodes each layer, activation functions and so on, to make the
optimum choice of hyperparameters is often thought as impossible, and most of the time it relies on
the instincts from researchers’ previous experience instead of theoretical support.
The lack of a common objective in representation learning makes it very difficult to measure
the “goodness” of the representation. Usually, we refer to the “usefulness” of representations in re­
lated supervised tasks as an indirect measurement. Another thing needs to be pointed out is that since
the unsupervised models are not directly trained with the supervised objective, the downstream su­
pervised tasks’ performance is not theoretically guaranteed to be improved, although such regime
empirically shows boosted performance in related supervised tasks.
The interpretability of the learned representation is another critical aspect of applications of
representation learning over multi­omics studies, since in biomedical studies, the findings are ex­
pected to be used to answer fundamental biological problems or elucidate the new biological mecha­
nism, and in the end ideally support or aid clinicians’ bedside decisions. Without appropriate biolog­
ically meaningful interpretation, the success in machine learning tasks will not necessarily guarantee
the acceptance from domain experts such as biologists and clinicians.
Therefore, developing practical unsupervised representation learning methods targeted on
biomedical problems requires us to introduce the most salient related prior knowledge into the model
design as well as the learning process. In the works included in my thesis, by leveraging the hier­
archical relationships among omics data at different levels, I proposed Cross­LEvel Information
Transmission network (CLEIT). CLEIT aims at the predictive modeling of genotype­phenotype as­
sociations by explicitly modeling the asymmetric cross­level information transmission in the biolog­
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ical system. When applied to the task of the anti­cancer drug sensitivity prediction, CLEIT could
improve such task’s performance when only somatic mutation data is available.
Moreover, via explicitly de­confounding the con­founding factors such as data source origins,
I proposed COherent DE­confounding Autoencoder (CODE­AE). CODE­AE is capable of learn­
ing an encoding function that maps a gene expression profile to a low­dimensional vector (embed­
ding)dominated by intrinsic biological signals from both in­vitro cell lines and in­vivo tissue samples.
It could improve patient drug response prediction from a supervised neural network model trained
from only in­vitro cell line data.
Despite the progress made, unsupervised representation learning’s application to multi­omics
data studies is still in its early stage. Innovative ideas and designs are in desperate needs to uncover
the underlying biological knowledge of the ever­increasing biomedical datasets and better understand
the complete biological system. In particular, for multi­omics datasets, techniques such as attention
mechanism [126] and graph neural network [127] could be incorporated into existing frameworks,
such as CLEIT and CODE­AE, such that the interactions between biological entities (i.e. genes)
could be used to improve the overall performance. Another critical direction is to devise innovative
approaches to organize the available datasets and design appropriate self­supervised learning tasks
for the model training such that to further relieve the needs for labeled datasets.
The overall machine learning applications in biomedical studies are still far away from its own
”BERT” [8] moment. However, with the constant emergence of more effective and accurate bio­
sensing techniques, we will be able to access biomedical dataset at even more granular levels, such
as the single cell sequencing [128], which will boost our chances to achive more accurate modelling
over diverse biomedical problems. Undoubtedly, the hope remains high, the mystery around human
body and biology will be solved scientifically in the future.
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